Aegon Ltd. Interim financial information for the six-month period ended June 30, 2026, dated August 20, 2026, is attached hereto and incorporated by reference herein and into the registration statements on Form S-8 (File No. 333-238186) and Form F-3 (No. 333-287291) of Aegon Ltd.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aegon Ltd. | ||||||
| (Registrant) | ||||||
| Date: August 20, 2026 | By | /s/ S. Knol | ||||
| S. Knol | ||||||
| Director Financial Reporting & Operations | ||||||
Interim Financial Informations For the six-month period ended June 30, 2026 August 20, 2026
|
||||
Table of contents
| 24 | ||
| 25 | ||
| 26 | ||
| 26 | ||
| 26 | ||
| 27 | 10 Fair value | |
| 29 | ||
| 31 | 12 (Re)Insurance contracts and investment contracts with discretionary participation features | |
| 36 | 13 Investment contracts without discretionary participation features | |
| 37 | 14 Borrowings | |
| 37 | ||
| 39 | ||
| 40 | ||
| 40 | ||
| 40 | ||
| 44 | ||
| 45 | Disclaimer | |
| 4 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
| Our performance | ||||
Our performance
In the first half of 2026, we continued to grow our businesses, delivered robust financial results and progressed at pace with our planned relocation to the US. These results demonstrate our strategy is gaining momentum and reinforce our confidence in the ambitions outlined at our 2025 Capital Markets Day.
Transamerica delivered strong commercial growth compared with the prior year period. Individual Life sales grew by 54%, fueled by growth in the instant decision market. We further expanded our distribution capabilities, with World Financial Group now exceeding 100,000 agents, and we maintained good commercial momentum in Retirement Plans written sales. Aegon Asset Management benefited from third-party net flows and positive market developments, and our International businesses continued to grow, led by Brazil.
We made significant progress in preparing for our future in the US. We selected New York City as the future location of our head office and announced changes to our leadership team. We reached an agreement with Vereniging Aegon, our largest shareholder, on its future relationship with our company and a proposed US-aligned governance framework. As previously announced, and in the context of our increased US focus, we also announced the sale of Aegon UK to Standard Life. Finally, we target an Extraordinary General Meeting on October 8, 2026, to seek shareholder approval for the redomiciliation to the US.
In the first half of 2026, net result amounted to EUR 608 million, stable compared with the prior year period, operating result increased by 9% to EUR 804 million and operating capital generation grew by 27% to EUR 416 million, enabling EUR 392 million in free cash flow. We also conducted our annual assumptions review, mostly to adjust for changing policyholder behavior observed in recent periods.
We are announcing an interim dividend of 21 eurocents per share, up 11% versus the prior year period. Supported by our strong capital position and confidence in the outlook for our businesses, we are also increasing our recently announced share buyback program by EUR 150 million to EUR 350 million. Our businesses are well capitalized and we are on track to meet or exceed our Group financial ambitions for 2026.
Strategic developments
On December 10, 2025, at the CMD (Capital Markets Day), Aegon announced its ambition to become a leading US life insurance and retirement group and its decision to move its head office and legal seat to the US. The redomiciliation process is running at pace with a number of developments underway:
| • | Implementation of US GAAP on track for a first release of the full-year 2027 results |
| • | Ensuring leadership continuity, Lard Friese’s term as Executive Director and CEO extended until the end of 2030 AGM. Will Fuller to become President and Chief Operating Officer of Aegon Ltd. from January 1, 2027 |
| • | New York City selected as the location for the future head-office |
| • | Sale of Aegon UK to Standard Life for a total consideration of GBP 2.0 billion. The transaction is expected to close around the end of 2026, subject to customary conditions, including regulatory approvals. The consideration at completion includes 181 million shares in Standard Life (worth GBP 1.25 billion upon announcement on April 15, 2026) and GBP 649 million in cash after the deduction of the expected remittance paid to Aegon over the course of 2026 |
| • | Issuance of USD 500 million senior unsecured note, trading on the New York Stock Exchange (NYSE), establishing a US dollar yield curve to support future senior debt issuances in the US market |
| • | Agreement with Vereniging Aegon on the future relationship with the Group and the proposed US-aligned governance framework |
| • | Extraordinary General Meeting (EGM) on proposed US redomiciliation targeted for October 8, 2026 |
| • | EUR 137 million of expenses booked in aggregate on US GAAP implementation and redomiciliation since the second half of 2025 |
Revised financial ambitions
Following the announced sale of Aegon UK to Standard Life, Aegon’s Group financial ambitions for 2026 and 2027 were updated:
| • | The Group operating result run-rate is expected to grow by around 5% per annum, from a pro forma 2025 run-rate of EUR 1.3 – 1.5 billion |
| • | OCG after holding funding and operating expenses is expected to grow between 0% and 5% per annum from a pro forma 2025 run-rate of EUR 0.7 – 0.75 billion |
| • | Free cash flow run-rate is expected to increase at around 5% per annum from a pro forma 2025 run-rate of around EUR 0.68 billion. The free cash flow growth ambition of around 5% per annum does not include remittances from Aegon UK or dividends from Standard Life |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 5 |
|
||||
| • | Dividend per share is expected to grow in excess of 5% per annum, which remains unchanged from the 2025 CMD financial ambition |
In addition, subsequent to the announcement at the 2025 CMD, Aegon has completed the transfer of Transamerica Asset Management (TAM) from Transamerica to Aegon Asset Management (AAM) resulting in the following updated financial ambitions for Transamerica and AAM, with no impact on Group financial ambitions for 2026 and 2027.
| • | Transamerica’s operating result run-rate is expected to grow by around 5% per annum, starting from a pro forma 2025 run-rate of USD 1.35 – USD 1.55 billion |
| • | Transamerica’s OCG run-rate is expected to grow between 0% and 3% per annum, starting from a pro forma 2025 run-rate of USD 0.86 – 0.96 billion |
| • | Transamerica’s remittance run-rate is expected to grow by around 5% per annum, starting from a pro forma 2025 run-rate of USD 645 million |
| • | AAM’s pro forma 2025 operating result, OCG and remittance run-rates are increased to EUR 210 - 240 million, EUR 150 - 170 million and EUR 110 million, respectively, with growth trends in line with the 2025 CMD financial ambitions |
Business update
Business update Americas
During the first half of 2026, Transamerica continued to make progress in growing its business by focusing on “Main Street” America, targeting the middle and mass affluent markets through agency distribution and the workplace. New Individual Life sales increased by 54% in the period compared with the first half of 2025, mainly driven by growth in the instant decision market through the brokerage channel and WFG, Transamerica’s affiliated distribution network of independent agents. WFG’s number of licensed agents surpassed the 100,000 agents mark and the company increased both its new life and annuity sales. Retirement Plans improved the return on Retirement Plans assets to 10 bps from spread expansion and experienced net outflows.
Strategic Assets business update: Distribution
| Amounts in USD millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| Distribution KPIs |
||||||||||||
| New life sales1,2,3 | 370 | 353 | 5 | |||||||||
| Total annuities sales1,2 |
2,680 | 2,383 | 12 | |||||||||
| Number of World Financial Group (WFG) licensed agents2 |
100,294 | 90,315 | 11 | |||||||||
| Transamerica’s market share in WFG (US Life) |
70% | 66% | ||||||||||
| 1 | Includes WFG and other distribution networks owned by Transamerica. |
| 2 | Totals reflect US and Canada. |
| 3 | New life sales is defined as new recurring premiums plus 1/10 of single premiums. |
In the first half of 2026 new life sales in the Distribution segment increased by 5%, driven by improved WFG agent productivity from more agents producing and a higher average premium per new policy sold. Annuities sales increased by 12% over the same period reflecting higher WFG segregated funds sales in Canada and higher annuities sales through Transamerica’s own financial adviser channel in the US.
Within WFG, the number of licensed agents increased to 100,294, reflecting improved agent retention and a higher activation rate of newly recruited agents. Furthermore, Transamerica’s market share of WFG US Life sales increased to 70% in the reporting period.
Strategic Assets business update: Savings & Investments
| Amounts in USD millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| Savings & Investments KPIs |
||||||||||||
| Gross deposits Retirement Plans | 17,307 | 18,643 | (7 | ) | ||||||||
| Net deposits Retirement Plans | (5,064 | ) | 2,149 | n.m. | ||||||||
| Retirement Plans AuA | 269,014 | 239,812 | 12 | |||||||||
| of which: General Account Stable Value AuM |
15,318 | 14,190 | 8 | |||||||||
| of which: Individual Retirement Accounts AuA |
16,457 | 13,592 | 21 | |||||||||
| Return on Retirement Plans Assets (RoA) in bps | 10 | 8 | 37 | |||||||||
| * | n.m. – not measured. |
Retirement Plans gross deposits decreased by 7% during the first half of 2026 compared with the prior year period, primarily due to a large pooled plan deposit of USD 1.9 billion reported in the first half of 2025. This was partly offset by higher recurring deposits reflecting strong written sales in previous periods and higher contributions from existing contracts. Written sales reflect good commercial momentum, especially within pooled plans, and are expected to support gross deposits in the coming quarters. Total net outflows amounted to USD 5.1 billion, of which USD 3.0 billion resulted from a contract termination following a merger. The remaining net outflows were driven by lower gross deposits and increased participant withdrawals, mainly resulting from higher account balances.
| 6 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
| Our performance | ||||
Favorable market movements drove a 12% increase in the total account balances in Retirement Plans compared with June 30, 2025. Continued strategies to grow ancillary products such as the General Account Stable Value product and Individual Retirement Accounts led to an 8% and 21% increase in asset balances of these products, respectively. Net fee revenues, also driven by Stable Value spread expansion, increased more than account balances and as a result the return on Retirement Plans assets improved by 2 bps to 10 bps.
Strategic Assets business update: Protection Solutions
| Amounts in USD millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| Protection Solutions KPIs | ||||||||||||
| Traditional Life |
184 | 80 | 130 | |||||||||
| Indexed Universal Life |
241 | 196 | 23 | |||||||||
| New life sales - Individual Life | 424 | 276 | 54 | |||||||||
| New life sales - Workplace Life | 41 | 49 | (16 | ) | ||||||||
| New premium production Workplace Health | 68 | 64 | 7 | |||||||||
| Net deposits Indexed Annuities | 1,100 | 993 | 11 | |||||||||
Individual Life new life sales increased by 54% in the first half of 2026 compared with the prior year period. The growth was mainly enabled by the fully digital underwriting platform with instant decision capabilities, driving strong sales in Final Expense and – since its launch on the platform in the fall of 2025 – in Indexed Universal Life (IUL). In addition, Indexed Universal Life sales by both WFG agents and Transamerica’s own agency channel increased in the reporting period.
New life sales in Workplace Life decreased compared with
the first half of 2025, while new premium production in Workplace Health peaked from the launch of a Medical Gap product and grew from the expansion of distribution partnerships for Supplemental Health products.
Net deposits for Indexed Annuities products increased by 11%. The increase was driven by a further improvement in wholesale distribution productivity and enhancements to the Registered Index Linked Annuities (RILA) products, including an income product option, as well as enhancements to crediting strategies and customer experience.
Financial Assets business update
| Amounts in USD millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| Financial Assets KPIs |
||||||||||||
| Capital employed in Financial Assets (at operating level) | 2,391 | 3,272 | (27 | ) | ||||||||
| Net deposits |
||||||||||||
| Variable Annuities |
(3,322 | ) | (2,980 | ) | (11 | ) | ||||||
| Fixed Annuities (excluding SPGAs and PAR annuities) | (187 | ) | (266 | ) | 29 | |||||||
| Net face amount Universal Life |
32,379 | 45,132 | (28 | ) | ||||||||
On June 30, 2026, Financial Assets had USD 2.4 billion of capital employed, a decrease of USD 0.9 billion compared with a year ago. A third of this decrease was driven by the reinsurance of a block of Secondary Guarantee Universal Life (SGUL) contracts, which was announced in December 2025. The transaction, together with existing reinsurance, resulted in 80% of the face value of Transamerica’s SGUL business being reinsured. The remaining part of the decrease in capital employed resulted mainly from favorable markets, the run-off of the Financial Assets book, and an expansion of the dynamic hedge program for Variable Annuities. Within Financial Assets, the required capital in Variable Annuities decreased in recent periods due to market movements. This may reverse if markets decline.
The run-off of the book and the reinsurance transaction resulted in a significantly lower net face value of the legacy Universal Life portfolio. In addition, the termination of purchased policies – which had previously been held by institutional investors – led to a further reduction in net face value in the first half of 2026. Transamerica expects to terminate the remaining purchased institutionally owned policies over the next few years.
Net outflows in Variable Annuities were 11% higher than in the prior year period, reflecting the run-off of the book, slightly offset by limited gross deposits from new business. Fixed Annuities net outflows resulted in similar amounts in the first half of 2026 compared with the same period in 2025.
Business update International
| Amounts in EUR millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| Spain & Portugal | 20 | 19 | 6 | |||||||||
| China | 37 | 48 | (23 | ) | ||||||||
| Brazil | 74 | 68 | 9 | |||||||||
| TLB and others | 12 | 10 | 25 | |||||||||
| New life sales | 143 | 144 | (1 | ) | ||||||||
| New premium production accident & health insurance | 26 | 26 | (1 | ) | ||||||||
| New premium production property & casualty insurance | 34 | 38 | (11 | ) | ||||||||
| * | Amounts include results from Aegon’s joint ventures and associates consolidated on a proportionate basis. |
International new sales continue to contribute to the ongoing growth of the book.
New life sales decreased by 1%, as growth in Brazil, Transamerica Life Bermuda (TLB), and Spain & Portugal was more than offset by a decrease in China. Brazil reported higher new life sales, driven by individual risk products, and favorable currency movements. At TLB, higher new life sales were driven by indexed universal life products while new life sales in Spain & Portugal benefited from higher credit linked sales compared with the prior year period. In China, lower sales were driven by the repricing of products to reflect the current economic environment.
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 7 |
|
||||
New premium production for accident and health insurance decreased mainly because the Health business in Spain focused on higher margin business to drive earnings growth. New premium production in property and casualty insurance decreased mainly due to lower sales of non-linked products in Spain through Santander Non-Life.
Business update Asset Management
| Amounts in EUR millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| General Account |
720 | 2,540 | (72 | ) | ||||||||
| Affiliate |
(338 | ) | (774 | ) | 56 | |||||||
| Third Party |
549 | 1,141 | (52 | ) | ||||||||
| Global Platforms | 931 | 2,907 | (68 | ) | ||||||||
| Affiliate |
(2,899 | ) | - | n.m. | ||||||||
| Third-party |
(948 | ) | - | n.m. | ||||||||
| Transamerica Asset Management | (3,847 | ) | - | n.m. | ||||||||
| Strategic Partnerships | 3,287 | 2,387 | 38 | |||||||||
| Net flows1,2 | 834 | 5,294 | (84 | ) | ||||||||
| Global Platforms | 267,819 | 258,099 | 4 | |||||||||
| Transamerica Asset Management | 57,548 | - | n.m. | |||||||||
| Strategic Partnerships | 77,646 | 62,596 | 24 | |||||||||
| Assets under Management1,2 | 390,359 | 320,695 | 22 | |||||||||
| 1 | Amounts include results from Aegon’s joint ventures and associates consolidated on a proportionate basis. |
| 2 | The total is corrected for AAM sub-advised funds, which is reported under both Transamerica Asset Management and Global Platforms. |
| 3 | n.m. – not measured. |
Strategic developments
As announced at the 2025 CMD, TAM was transferred from Transamerica to AAM on January 1, 2026 and the 2025 figures are not restated for this transfer.
Following the announced sale of Aegon UK to Standard Life, flows and Assets under Management (AuM) from Aegon UK, which were previously classified as General Account and Affiliate, will be classified as third-party from 2026, with prior year periods restated for consistent comparison.
Business update
In Global Platforms, during the first half of 2026, the General Account experienced net inflows driven by US liquid assets and private debt. This was partly offset by net outflows from AAM Real Assets.
Net outflows in Affiliate at both Global Platforms and TAM mainly reflected the run-off of the Financial Assets block in the US.
Third-party net flows were mainly driven by inflows in ABS and fixed income products in Europe. This was partly offset by outflows from a.s.r and from the gradual run-off of the traditional insurance book of Aegon UK. Third-party revenues increased by 1.5% to EUR 162 million in the first half of 2026 compared with the prior year period.
TAM experienced net outflows in third-party from short term bonds and International equities.
Net inflows in AAM’s Strategic Partnerships were driven by Aegon’s Chinese asset management joint venture, Aegon Industrial Fund Management Company (AIFMC), which benefited from net inflows into mutual funds and money market funds. This was partly offset by net outflows from Aegon’s French asset management joint venture, LBP AM, mainly driven by continued withdrawals of low-margin business from a former shareholder.
Assets under Management (AuM) increased by EUR 70 billion compared with June 30, 2025, mainly driven by the inclusion of TAM assets. Excluding the TAM assets, AuM increased driven by the impact of favorable markets, currency movements, and third-party net inflows. This was partially offset by net outflows mainly from the General Account driven by the reinsurance transaction on Transamerica’s SGUL block in the second half of 2025.
Financial highlights
Overview
| Amounts in EUR millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| Net result | 608 | 606 | - | |||||||||
| Operating result1 | 804 | 741 | 9 | |||||||||
| June 30, 2026 |
December 31, 2025 |
% | ||||||||||
| Shareholders’ equity | 7,328 | 7,432 | (1 | ) | ||||||||
| Contractual Service Margin (CSM)2 (pro-forma after tax) | 5,449 | 6,277 | (13 | ) | ||||||||
| Estimated equity accretion AUK sale | 1,214 | - | n.m. | |||||||||
| Valuation equity | 13,991 | 13,709 | 2 | |||||||||
| Gross financial leverage | 4,967 | 4,850 | 2 | |||||||||
| 1 | 1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| 2 | On IFRS basis i.e. excluding joint ventures & associates |
| * | n.m. – not measured. |
Net result
The result before tax amounted to EUR 715 million, as the positive impact from the operating result and non-operating items was partly offset by Other charges. The income tax for the period amounted to EUR 107 million and included recurring beneficial impacts, such as dividend received deduction and tax credits in the US. The net result, therefore, was EUR 608 million.
Operating result
Aegon uses the non-IFRS performance measure operating result that reflects Aegon’s profit before tax from underlying business operations and mainly excludes components that relate to accounting mismatches that are dependent on market volatility or relate to events that are considered outside the normal course of business. Aegon believes that
| 8 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
| Our performance | ||||
this performance measure provides meaningful information about the operating results of Aegon’s business, including insight into the financial measures that Aegon’s senior management uses in managing the business. The reconciliation from Result before tax from continuing operations, being the most directly comparable IFRS measure, to operating result is presented in note 3 Segment information included in the Notes to the condensed consolidated interim financial statements.
| Amounts in EUR millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| Distribution | 85 | 76 | 12 | |||||||||
| Savings & Investments | 128 | 115 | 11 | |||||||||
| Protection Solutions | 320 | 349 | (8 | ) | ||||||||
| Financial Assets | 115 | 87 | 33 | |||||||||
| Americas | 648 | 627 | 3 | |||||||||
| Spain & Portugal | 47 | 47 | - | |||||||||
| China (ATHTF) | 18 | 12 | 54 | |||||||||
| Brazil | 37 | 26 | 42 | |||||||||
| TLB | 27 | 20 | 39 | |||||||||
| Other | (6 | ) | (5 | ) | (21 | ) | ||||||
| International | 123 | 99 | 24 | |||||||||
| Global Platforms | 46 | 35 | 31 | |||||||||
| Transamerica Asset Management | 20 | - | n.m. | |||||||||
| Strategic Partnerships | 85 | 69 | 22 | |||||||||
| Asset Management | 150 | 104 | 44 | |||||||||
| Holding and other activities | (118 | ) | (89 | ) | (32 | ) | ||||||
| Operating result1 | 804 | 741 | 9 | |||||||||
| 1 | 1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| * | n.m. – not measured. |
Aegon’s operating result increased by 9% to EUR 804 million driven by an increase across all units, reflecting business growth and favorable market impacts.
Over the 2026-2027 period, Aegon aims to grow its operating result by around 5% per year, from the EUR 1.3 – 1.5 billion operating result run-rate in 2025 (taking into account the divestment of Aegon UK and an assumed EUR/ USD exchange rate of 1.20).
Americas
The operating result of the Americas increased by 3% to EUR 648 million in the first half of 2026.
In local currency, it increased by 10% to USD 756 million and is within the updated financial ambition range which has been updated for the previously announced transfer of TAM from the Americas to AAM. The increase in the operating result was 14% when excluding the contribution of TAM for both periods. Compared with the first half of 2025, the increase in the operating result was largely driven by business growth in the Strategic Assets, as well as by an improvement of experience variances in Financial Assets.
The operating result of the Distribution business segment increased by 19%. Net commission revenue from continued momentum in life and annuity sales more than offset increased expenses reflecting investments in the WFG franchise.
In the Savings & Investments business segment, the operating result increased by 19% to USD 150 million, which excludes the Mutual Funds business in this reporting period as the business was transferred to AAM. Correcting the prior year period figure for this transfer, the Savings & Investments operating result increased by 42%, largely driven by Retirement Plans. In this business, revenues increased from higher assets under administration driven by market performance and by growth in Individual Retirement Accounts and General Account Stable Value assets. Margin expansion from higher Stable Value spreads contributed to the operating result growth.
The operating result of the Protection Solutions business segment decreased by 2%. Portfolio growth resulted in a higher release of CSM and risk adjustment. Similar to the prior year reporting period, experience variances on claims, expenses, and other items from non-onerous contracts were favorable in this period, partly driven by favorable mortality in IUL and Variable Universal Life. These benefits were largely offset by unfavorable experience from onerous contracts, mainly reflecting policyholder behavior in Traditional Life.
The operating result of the Financial Assets segment increased by 42% to USD 135 million, as the experience variance on claims, premiums, and other items was slightly favorable compared with expectations, an improvement compared with last year. At the same time, the CSM release is lower due to the portfolio run-off.
Interest accretion for onerous Variable Annuities contracts, onerous new business, and expense experience variance for Financial Assets are considered recurring and are in aggregate similar to the prior year period.
As Transamerica continues to grow the business, it aims to grow the operating result by about 5% per year over the 2026-2027 period from a pro forma USD 1.35 – 1.55 billion operating result run-rate in 2025. The financial ambition is updated to reflect the transfer of TAM to AAM.
International
The operating result of the International segment increased by 24% to EUR 123 million in the first half of 2026 mainly driven by Brazil and TLB. In Brazil, the operating result benefited from business growth and higher investment income. TLB’s operating result benefited from favorable persistency experience partially offset by a lower net investment result from a lower asset balance because of remittances following the reinsurance arrangement between TLB and Transamerica. In Spain & Portugal, the operating result was stable as the impact of business growth was largely offset
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 9 |
|
||||
by adverse claims in household insurance from the storms in early 2026. China’s operating result increased driven by the local implementation of IFRS 17 which resulted in a higher operating result compared with the prior year, which was reported on a simplified IFRS 17 basis.
Asset Management
The operating result of AAM amounted to EUR 150 million in the first half of 2026. This includes the operating result of TAM of EUR 20 million. Excluding the impact of TAM, AAM’s operating result increased by 25% driven by strong performance of Global Platforms and Strategic Partnerships. In Global Platforms, the increase in operating result was mainly driven by lower expenses from ongoing expense management and higher revenues from favorable markets, enabling an increase in operating margin from 15.5% in the first half of 2025 to 20.2% in the reporting period. In Strategic Partnerships, the operating result increased, driven by AIFMC, which benefited from favorable markets resulting in both higher performance and management fees, and strong net flows in high margin funds.
Holding
The operating result of the Holding was a loss of EUR 118 million. The result from the Holding was lower compared with the prior year period mainly driven by a lower benefit from the internal reinsurance arrangement between TLB and Transamerica. In addition, the operating result was impacted by lower returns on Cash Capital at Holding due to lower short-term yields and a lower cash balance.
Non-operating items
| Amounts in EUR millions (unaudited) |
1H 2026 | 1H 20251 | % | |||||||||
| Operating result | 804 | 741 | 9 | |||||||||
| Fair value items | (7 | ) | 158 | n.m. | ||||||||
| Realized gains / (losses) on investments | 57 | (54 | ) | n.m. | ||||||||
| Net impairments | 21 | (5 | ) | n.m. | ||||||||
| Non-operating items | 71 | 98 | (28 | ) | ||||||||
| Other income / (charges)2 | (160 | ) | (128 | ) | (26 | ) | ||||||
| Result before tax | 715 | 711 | - | |||||||||
| Income tax | (107 | ) | (106 | ) | (1 | ) | ||||||
| Net result | 608 | 606 | - | |||||||||
| Interest on financial leverage classified as equity after tax | (37 | ) | (19 | ) | (93 | ) | ||||||
| Net result after interest on financial leverage classified as equity | 571 | 586 | (3 | ) | ||||||||
| Average common shareholders’ equity | 7,310 | 7,329 | - | |||||||||
| Return on Equity3 | 16.7% | 15.4% | ||||||||||
| 1 | 1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| 2 | Includes income tax chargeable to policyholders in the United Kingdom. |
| 3 | Operating result after tax and interest on financial leverage classified as equity / average common shareholders’ equity. |
| * | n.m. – not measured. |
The gain from non-operating items amounted to EUR 71 million in the first half of 2026, mainly driven by realized gains and net recoveries in the Americas.
Fair value items
Fair value items constituted a loss of EUR 7 million, mainly driven by the Holdings with an offset from the Americas. In the Holdings, fair value losses reflected interest rate hedge impacts related to debt instruments and mark-to-market revaluations related to TLB, including from the annual assumption updates. In the Americas, fair value items of EUR 25 million resulted from hedging gains of indexed products which were partly offset by the underperformance of private equity investments and lower property valuations of multi-family real estate assets.
Realized gains on investments
Realized gains on investments amounted to EUR 57 million driven by the Americas. Asset dispositions as part of normal trading activity and the full repayment of the mortgage loans related to the Transamerica Pyramid complex in San Francisco resulted in gains from expected credit loss (ECL) reversals.
Net impairments
Net impairments reflected a recovery in the first half of 2026 of EUR 21 million driven by the Americas. Improved macroeconomic and market conditions resulted in favorable releases from the ECL reserve, which were only partly offset by additions to the ECL reserve from purchases of new assets.
Other charges
Other charges in the first half of 2026 amounted to EUR 160 million largely driven by the Americas, and were partially offset by the positive result from Aegon’s stake in a.s.r. of EUR 201 million and positive result of EUR 10 million from the Aegon UK business which is held for sale.
The annual model and assumption review in the Americas resulted in EUR 294 million charges, mainly addressing policyholder behavior experience variances which resulted in higher-than-expected premium persistency in older Universal Life policies and lower-than-expected lapses of Traditional Life policies. In addition, mortality assumptions were updated, also to reflect lower mortality improvement, leading to Other charges mainly for onerous, older life policies with some favorable offsets from annuities.
Other charges also included investments and restructuring charges related to the transformation of our businesses and the relocation of our head office and legal seat to the US, including US GAAP implementation expenses.
| 10 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
| Our performance | ||||
Balance sheet items
| Amounts in EUR millions (unaudited) | June 30, 2026 |
December 31, 2025 |
% | |||||||||
| Shareholders’ equity | 7,328 | 7,432 | (1 | ) | ||||||||
| Shareholders’ equity per share (in EUR) | 4.94 | 4.91 | - | |||||||||
| Americas | 6,731 | 6,359 | 6 | |||||||||
| United Kingdom | - | 1,555 | n.m. | |||||||||
| International | 312 | 262 | 19 | |||||||||
| Eliminations | (102 | ) | (111 | ) | 8 | |||||||
| Contractual Service Margin1 | 6,941 | 8,066 | (14 | ) | ||||||||
| Pro-forma tax | (1,492 | ) | (1,789 | ) | 17 | |||||||
| CSM after tax | 5,449 | 6,277 | (13 | ) | ||||||||
| CSM after tax per share (in EUR) | 3.67 | 4.15 | (12 | ) | ||||||||
| Estimated equity accretion AUK sale | 1,214 | - | n.m. | |||||||||
| Valuation equity | 13,991 | 13,709 | 2 | |||||||||
| Valuation equity per share (in EUR) | 9.42 | 9.06 | 4 | |||||||||
| Gross financial leverage | 4,967 | 4,850 | 2 | |||||||||
| Gross financial leverage ratio (%) | 26.0% | 25.9% | ||||||||||
| 1 | On IFRS basis, i.e. excluding joint ventures & associates. |
| * | n.m. – not measured. |
Shareholders’ equity
As of June 30, 2026, shareholders’ equity amounted to EUR 7.3 billion, a decrease compared with December 31, 2025. Capital distributions to shareholders (which include both the EUR 227 million share buyback and EUR 313 million corresponding to the 2025 final dividend paid in July 2026) and the impact of revaluations were partly offset by the positive net result and favorable currency movements.
On a per share basis, shareholders’ equity increased to EUR 4.94.
Valuation equity
Valuation equity is a non-IFRS financial measure that represents the sum of shareholders’ equity and CSM after tax (embedded value of unearned profits in insurance contracts). This measure is intended to provide a more comprehensive view of the Group’s economic value. The reconciliation from shareholders’ equity, being the most directly comparable IFRS measure, to valuation equity is presented in the above table.
As of June 30, 2026, valuation equity includes EUR 1,214 million estimated shareholders’ equity accretion resulting from the announced sale of Aegon UK to Standard Life. This reflects the expected economic value impact of the transaction and more than offsets the exclusion of the Aegon UK CSM after tax subsequent to the announcement of the sale.
Valuation equity increased to EUR 14.0 billion in the reporting period, mainly driven by the positive net result and favorable currency movements. These were largely offset by EUR 540 million capital distributions to shareholders and the unfavorable impact of EUR 231 million from the annual assumption review in aggregate, split across different P&L and balance sheet items.
On a per share basis, valuation equity increased by 4% to EUR 9.42.
Gross financial leverage
Gross financial leverage increased by EUR 0.1 billion in the first half of 2026. This increase was driven by the new issuance of USD 500 million senior debt exceeding the tender offer on subordinated notes.
Contractual Service Margin (CSM)
| Amounts in EUR millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| CSM at beginning of period | 8,572 | 8,990 | (5 | ) | ||||||||
| New business | 413 | 337 | 22 | |||||||||
| CSM release | (450 | ) | (492 | ) | 9 | |||||||
| Accretion of interest | 139 | 125 | 11 | |||||||||
| Claims and policyholder experience variance | (108 | ) | (240 | ) | 55 | |||||||
| Non-financial assumption changes | 3 | (336 | ) | n.m. | ||||||||
| Non-disaggregated risk adjustment | 94 | 65 | 44 | |||||||||
| Market impact on unhedged risk of VFA products | 57 | 248 | (77 | ) | ||||||||
| Net exchange differences | 222 | (912 | ) | n.m. | ||||||||
| Transfer to disposal groups | (1,457 | ) | - | n.m. | ||||||||
| Other movements | (3 | ) | - | n.m. | ||||||||
| CSM at end of period | 7,484 | 7,786 | (4 | ) | ||||||||
| * | n.m. – not measured. |
During the reporting period, the CSM balance decreased to EUR 7.5 billion, mainly driven by the exclusion of Aegon UK which is held for sale. On a comparable basis, adjusted for the sale of Aegon UK, the CSM balance increased from EUR 7.0 billion to EUR 7.5 billion over the first half of 2026.
New business contributed EUR 413 million to the CSM and together with interest accretion of EUR 139 million more than offset the CSM release of EUR 450 million.
Claims and policyholder experience variance negatively impacted the CSM, mainly driven by US Financial Assets, partly offset by favorable experience in US Strategic Assets. Favorable currency movements – predominantly the appreciation of the US Dollar versus the Euro – increased the CSM balance in addition to non-disaggregated risk adjustment and favorable market movements.
Americas
In the Americas, the CSM balance grew to EUR 6.7 billion, or USD 7.7 billion, at June 30, 2026. This was driven by a growth of 30% of the CSM balance in Strategic Assets (Protection Solutions) compared with a year ago and was only partly offset by the run-off of Financial Assets, where the CSM decreased by 13% over the year. The CSM balance of Protection Solutions now accounts for 61% of the total Americas CSM. For the first time since the introduction of IFRS 17, the addition to CSM from new business was larger than the release of CSM, demonstrating the success of Transamerica’s strategy to grow its Strategic Assets and reduce its exposure to Financial Assets.
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 11 |
|
||||
In the first half of 2026, the increase of the CSM balance of Protection Solutions was mainly driven by new business, which, in addition to the accretion of interest, largely reflects growth of the IUL and Traditional Life portfolios; this is also reflected in the increase of the release of CSM. Favorable non-financial assumption changes mainly reflected lower future mortality in younger life insurance policies and improved spread and profitability assumptions in the IUL product. This was partly offset by unfavorable higher-than-expected usage of accelerated living benefits and adverse lapse experience on Traditional Life products.
The Financial Assets CSM balance decreased in the period from the gradual run-off of the portfolios, only partly offset by the accretion of interest and new business. Also, in Variable Annuities, decrements and withdrawal variances were unfavorable to the CSM, but were partly offset by favorable impacts from positive equity markets. In addition, non-financial assumption changes had an unfavorable impact reflecting the more efficient use of withdrawals and surrenders of Variable Annuities policyholders, which was partly offset by the favorable impact of lower mortality rate assumptions in annuities. The non-disaggregated risk adjustment provided an offset improving the CSM.
Capital highlights
Capital ratios
| Amounts in millions (unaudited) | June 30, 2026 |
December 31, 2025 |
% | |||||||||
| Group solvency ratio (EUR) | ||||||||||||
| Available own funds | 11,653 | 12,149 | (4 | ) | ||||||||
| Non-eligible own funds | (275 | ) | (248 | ) | (11 | ) | ||||||
| Eligible own funds | 11,378 | 11,901 | (4 | ) | ||||||||
| Consolidated Group SCR | 6,715 | 6,464 | 4 | |||||||||
| Group Solvency ratio | 169% | 184% | ||||||||||
| Americas (USD) | ||||||||||||
| Total adjusted capital (TAC) | 6,988 | 7,276 | (4 | ) | ||||||||
| RBC required capital (100% CAL) | 1,665 | 1,715 | (3 | ) | ||||||||
| US RBC ratio | 420% | 424% | ||||||||||
| Scottish Equitable plc (GBP) | ||||||||||||
| Own funds | 2,308 | 2,128 | 8 | |||||||||
| SCR | 1,224 | 1,163 | 5 | |||||||||
| Solvency UK ratio | 189% | 183% | ||||||||||
Group solvency ratio
The estimated Group solvency ratio decreased to 169% on June 30, 2026, compared with December 31, 2025. This was mainly driven by the loss of capital eligibility of the Perpetual Capital Subordinated Bonds (PCSBs) and the impact of the tender offer on subordinated notes (-9%- points), the EUR 350 million share buyback program for the second half of 2026 and the announced 2026 interim dividend (-10%-points). Total capital generation amounted to EUR 211 million (+4%-points). This included market movements with a negative impact of EUR 146 million, mostly driven by the US. Furthermore, one-time items were unfavorable at EUR 59 million, reflecting the adverse impact of model and assumption changes, mainly in the US, which were partially offset by the contribution from Aegon UK and the a.s.r. stake.
Aegon is accelerating the implementation of Group regulatory reporting under the Bermuda solvency framework from full-year 2027 to full-year 2026, with the Group solvency ratio expected to remain broadly in line with current levels and no impact on Aegon’s capital management framework.
Under the new aggregation approach for Group solvency, on a pro forma basis, the completion of the sale of Aegon UK is expected to have a positive impact of around 10%-points on the Group solvency ratio.
US RBC ratio
The estimated RBC ratio amounted to 420% on June 30, 2026, remaining above the operating level of 400%. OCG from the operating entities applying the RBC framework benefited the ratio by 31%-points in the first half of 2026 and was partially offset by a 12%-points unfavorable impact from remittances in the period (as part of the remittances to the Holding was funded by entities outside the RBC framework). One-time items and management actions negatively impacted the RBC ratio by 11%-points in the first half of 2026, mostly due to the unfavorable impact of the annual actuarial assumption and model updates and, to a lesser extent, negative impacts from restructuring expenses, and various other items. Market movements had a 12%-points negative impact on the ratio in the reporting period. This was driven by the underperformance of private equity investments and non-economic losses on energy-related assets under the statutory framework, as well as fund basis risk impacts and cross effects between asset classes in the Variable Annuities portfolio.
Solvency UK ratio
The estimated Solvency UK ratio for Scottish Equitable plc increased to 189% as of June 30, 2026, and remained above the operating level of 150%. The increase was mainly driven by the impact of OCG and favorable market movements. This was partly offset by remittances to the Holding and investments to strengthen the business.
| 12 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
| Our performance | ||||
Cash capital at Holding and free cash flow
| Amounts in EUR millions (unaudited) | 1H 2026 | 1H 2025 | % | |||||||||
| Beginning of period | 1,311 | 1,725 | (24 | ) | ||||||||
| Americas | 308 | 259 | 19 | |||||||||
| United Kingdom | 11 | 61 | (83 | ) | ||||||||
| International | 21 | 40 | (49 | ) | ||||||||
| Asset Management | 46 | 71 | (35 | ) | ||||||||
| a.s.r. dividends |
104 | 121 | (14 | ) | ||||||||
| a.s.r. share buybacks |
42 | 38 | 13 | |||||||||
| Cash flows from a.s.r. | 146 | 159 | (8 | ) | ||||||||
| Gross remittances | 531 | 590 | (10 | ) | ||||||||
| Funding and operating expenses | (139 | ) | (148 | ) | 6 | |||||||
| Free cash flow | 392 | 442 | (11 | ) | ||||||||
| Capital injections | (1 | ) | (34 | ) | 98 | |||||||
| Divestitures and acquisitions | 59 | 26 | 127 | |||||||||
| Share buybacks and other flows from / (to) shareholders | (200 | ) | (110 | ) | (82 | ) | ||||||
| Net change in gross financial leverage | 107 | (9 | ) | n.m. | ||||||||
| Other | (11 | ) | (28 | ) | 58 | |||||||
| End of period | 1,656 | 2,011 | (18 | ) | ||||||||
| * | n.m. – not measured. |
Aegon’s Cash Capital at Holding increased during the first half of 2026, largely driven by remittances from the business units, partly offset by capital returns to shareholders in the form of share buybacks. Free cash flow included the 2025 final dividend from a.s.r. and Aegon’s participation in a share buyback program by a.s.r. Following the announcement of the sale of Aegon UK to Standard Life, Aegon UK remittances are reflected in divestitures and acquisitions in the first half of 2026. Except for a dividend from Cornerstone - a small entity outside the transaction perimeter which is being wound down - with the liquidation proceeds reported in free cash flow. Remittances from International only reflected the contribution from Portugal as the full remittances from Spain and TLB are expected to be received during the second half of 2026. As a result, and excluding the contribution from Aegon UK, free cash flow was flat compared to the prior year period. The Cash Capital at Holding also reflects the net cash proceeds from the senior bond issuance and the tender offer in the second quarter, partly offset by other items, which include the EUR 27 million share buyback to meet Aegon’s obligations related to share-based compensation plans for senior management.
Over the 2026-2027 period, Aegon aims to grow its free cash flow – excluding remittances from Aegon UK or dividends from Standard Life – by around 5% per year, from around EUR 0.68 billion run-rate in 2025 (taking into account the divestment of Aegon UK and an assumed EUR/USD exchange rate of 1.20).
2026 interim dividend
Aegon aims to pay a sustainable dividend to allow equity investors to participate in the company’s performance, which can grow over time if Aegon’s performance allows. At our 2025 CMD, Aegon set a financial ambition for dividend growth of more than 5% per annum. Aegon today announces an interim dividend for 2026 of EUR 0.21 per common share, which represents an increase of EUR 0.02 or 11% compared with the interim dividend for 2025.
Aegon’s shares will be quoted ex-dividend on September 2, 2026. The record date for the dividend will be September 3, 2026, and the dividend will be payable as of September 24, 2026.
Share buyback programs
At our 2025 CMD, we announced a new EUR 400 million share buyback program to be split evenly between the first and the second half of 2026. On January 12, 2026, Aegon announced a EUR 227 million share buyback, which reflected both the first half of the EUR 400 million share buyback program and EUR 27 million to meet Aegon’s obligations related to share-based compensation plans for senior management. This EUR 227 million share buyback program was completed on June 30, 2026.
On July 1, 2026, Aegon announced the beginning of a EUR 200 million share buyback program, which reflects the second half of the EUR 400 million share buyback program. Aegon today announces that it will be increasing this ongoing EUR 200 million share buyback program by an additional EUR 150 million to a total amount of EUR 350 million, consistent with its objective to reduce Cash Capital at Holding to around EUR 1.0 billion by the end of 2026. Barring unforeseen circumstances, this EUR 350 million share buyback is expected to be completed on or before December 23, 2026.
Exchange rates
| Weighted average rate | Closing rate | |||||||||||||||
| Per 1 EUR |
1H 2026 | 1H 2025 | |
June 30, 2026 |
|
|
December 31, 2025 |
| ||||||||
| USD |
1.1667 | 1.0934 | 1.1417 | 1.1733 | ||||||||||||
| GBP |
0.8673 | 0.8424 | 0.8612 | 0.8727 | ||||||||||||
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 13 |
|
||||
| Amounts in EUR millions (except per share data) | Note |
1H 2026 |
1H 2025 1 | |||||||
| Continuing operations |
||||||||||
| Insurance revenue |
||||||||||
| Insurance service expenses |
7 |
( |
) | ( | ||||||
| Net income / (expenses) on reinsurance held |
||||||||||
| Insurance service result |
4 |
|||||||||
| Interest revenue on financial instruments calculated using the effective interest method |
||||||||||
| Interest income from instruments measured at FVPL |
||||||||||
| Other investment income |
||||||||||
| Results from financial transactions |
5.2 |
|||||||||
| Impairment (losses) / reversals |
( | |||||||||
| Insurance finance income / (expenses) |
( |
) | ( | |||||||
| Net reinsurance finance income / (expenses) on reinsurance held |
||||||||||
| Interest expenses |
( |
) | ( | |||||||
| Insurance net investment result |
5.1 |
|||||||||
| Interest revenue on financial instruments calculated using the effective interest method |
||||||||||
| Interest income from instruments measured at FVPL |
||||||||||
| Other investment income |
||||||||||
| Results from financial transactions |
5.2 |
|||||||||
| Impairment (losses) / reversals |
( | |||||||||
| Investment contract income / (expenses) |
( |
) | ( | |||||||
| Interest expenses |
( |
) | ( | |||||||
| Other net investment result |
||||||||||
| Interest charges |
( |
) | ( | |||||||
| Financing net investment result |
( |
) |
( | |||||||
| Total net investment result |
5 |
|||||||||
| Fees and commission income |
6 |
|||||||||
| Other operating expenses |
7 |
( |
) | ( | ||||||
| Other income / (charges) |
||||||||||
| Other result |
( |
) |
( | |||||||
| Result before share in profit / (loss) of joint ventures, associates and tax |
||||||||||
| Share in profit / (loss) of joint ventures |
||||||||||
| Share in profit / (loss) of associates |
||||||||||
| Result before tax from continuing operations |
||||||||||
| Income tax (expense) / benefit |
8 |
( |
) | ( | ||||||
| Net result from continuing operations |
||||||||||
| Discontinued operations |
||||||||||
| Net result from discontinued operations |
19 |
|||||||||
| Net result from continuing and discontinued operations |
||||||||||
| Net income/ (loss) attributable to: |
||||||||||
| Owners of Aegon Ltd. |
||||||||||
| Non-controlling interests |
( |
) | ||||||||
| Earnings per share from continuing and discontinued operations |
11.3 |
|||||||||
| Basic earnings per common share |
||||||||||
| Basic earnings per common share B |
||||||||||
| Diluted earnings per common share |
||||||||||
| Diluted earnings per common share B |
||||||||||
| Earnings per share from continuing operations |
||||||||||
| Basic earnings per common share from continuing operations |
||||||||||
| Basic earnings per common share B from continuing operations |
||||||||||
| Diluted earnings per common share from continuing operations |
||||||||||
| Diluted earnings per common share B from continuing operations |
||||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| 14 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Condensed consolidated interim financial statements of Aegon Ltd. | ||||
| Amounts in EUR millions | Note |
1H 2026 |
1H 2025 1 | |||||||
Net result from continuing and discontinued operations |
||||||||||
Items that will not be reclassified to profit or loss: |
||||||||||
Gains/ (losses) on investments in equity instruments (FVOCI) |
( | |||||||||
Remeasurements of defined benefit plans |
( |
) | ( | |||||||
Income tax relating to items that will not be reclassified |
||||||||||
Discontinued operations that will not be reclassified |
19 |
( |
) | |||||||
Insurance items that may be reclassified subsequently to profit or loss: |
||||||||||
Unrealized gains / (losses) on financial assets (FVOCI) |
5 |
( |
) | |||||||
Realized gains / (losses) on disposal of financial assets (FVOCI) |
5 |
( |
) | |||||||
Insurance finance income / (expenses) |
5 |
( | ||||||||
Reinsurance finance income / (expenses) |
5 |
( |
) | |||||||
Changes in cash flow hedging reserve |
( | |||||||||
Income tax relating to items that may be reclassified |
( | |||||||||
Items that may be reclassified subsequently to profit or loss: |
||||||||||
Unrealized gains / (losses) on financial assets (FVOCI) |
( |
) | ||||||||
Realized gains / (losses) on disposal of financial assets (FVOCI) |
( |
) | ||||||||
Changes in cash flow hedging reserve |
( | |||||||||
Movements in foreign currency translation and net foreign investment hedging reserves |
( | |||||||||
Equity movements of joint ventures |
( |
) | ||||||||
Equity movements of associates |
||||||||||
Disposal |
( |
) | ( | |||||||
Income tax relating to items that may be reclassified |
( | |||||||||
Discontinued operations that may be reclassified |
19 |
( | ||||||||
Other |
( |
) | ( | |||||||
Total other comprehensive income / (loss) |
( |
) |
( | |||||||
Total comprehensive income / (loss) |
||||||||||
Total comprehensive income/ (loss) attributable to: |
||||||||||
Owners of Aegon Ltd. |
||||||||||
Non-controlling interests |
( |
) | ||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 15 |
|
||||
| Amounts in EUR millions | Note |
June 30, 2026 |
December 31, 2025 | |||||||
Assets |
||||||||||
Cash and cash equivalents |
||||||||||
Assets held for sale |
19 |
|||||||||
Investments |
9 |
|||||||||
Derivatives |
||||||||||
Investments in joint ventures |
||||||||||
Investments in associates |
||||||||||
Reinsurance contract assets |
12 |
|||||||||
Insurance contract assets |
12 |
|||||||||
Deferred tax assets |
||||||||||
Deferred expenses |
||||||||||
Other assets and receivables |
||||||||||
Intangible assets |
||||||||||
Total assets |
||||||||||
Equity and liabilities |
||||||||||
Shareholders’ equity |
11 |
|||||||||
Other equity instruments |
11.6 |
|||||||||
Issued capital and reserves attributable to owners of Aegon Ltd. |
||||||||||
Non-controlling interests |
||||||||||
Group equity |
||||||||||
Subordinated borrowings |
||||||||||
Trust pass-through securities |
||||||||||
Reinsurance contract liabilities |
12 |
|||||||||
Insurance contract liabilities |
12 |
|||||||||
Investment contract liabilities with discretionary participation features |
12 |
|||||||||
Investment contracts without discretionary participation features |
13 |
|||||||||
Derivatives |
||||||||||
Borrowings |
14 |
|||||||||
Liabilities held for sale |
19 |
|||||||||
Other liabilities |
||||||||||
Total liabilities |
||||||||||
Total equity and liabilities |
||||||||||
| 16 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Condensed consolidated interim financial statements of Aegon Ltd. | ||||
| Amounts in EUR millions | Share capital |
Retained earnings |
Revaluation reserves |
Remeasurement of defined benefit plans |
Other reserves |
Other equity instruments |
Reserve of discontinued operations held for sale |
Issued capital and reserves 1 |
Non- controlling interests |
Total | ||||||||||||||||||||||||||||||
On January 1, 2026 |
( |
) |
( |
) |
- |
|||||||||||||||||||||||||||||||||||
| Net result recognized in the income statement | - | - | - | - | - | - | ( |
) | ||||||||||||||||||||||||||||||||
Other comprehensive income: |
||||||||||||||||||||||||||||||||||||||||
Items that will not be reclassified to profit or loss: |
||||||||||||||||||||||||||||||||||||||||
| Remeasurements of defined benefit plans | - | - | - | ( |
) | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
| Income tax relating to items that will not be reclassified | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Discontinued operations that will not be reclassified | - | - | - | - | - | ( |
) | ( |
) | - | ( |
) | ||||||||||||||||||||||||||||
Insurance items that may be reclassified subsequently to profit or loss: |
||||||||||||||||||||||||||||||||||||||||
| Unrealized gains / (losses) on financial assets (FVOCI) | - | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
| Realized gains / (losses) on disposal of financial assets (FVOCI) | - | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
| Insurance finance income / (expenses) | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Reinsurance finance income / (expenses) | - | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
| Changes in cash flow hedging reserve | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Income tax relating to items that may be reclassified | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
Items that may be reclassified subsequently to profit or loss: |
||||||||||||||||||||||||||||||||||||||||
| Unrealized gains / (losses) on financial assets (FVOCI) | - | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
| Realized gains / (losses) on disposal of financial assets (FVOCI) | - | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
| Changes in cash flow hedging reserve | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Movements in foreign currency translation and net foreign investment hedging reserves | - | - | ( |
) | ( |
) | - | - | ||||||||||||||||||||||||||||||||
| Equity movements of joint ventures | - | - | - | ( |
) | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||||||
| Equity movements of associates | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Disposal | - | - | - | ( |
) | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||||||
| Income tax relating to items that may be reclassified | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||
| Discontinued operations that may be reclassified | - | - | - | - | - | ( |
) | - | ||||||||||||||||||||||||||||||||
| Other | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||||||
Total other comprehensive income / (loss) |
- |
( |
) |
( |
) |
- |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Total comprehensive income / (loss) |
- |
( |
) |
- |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
| Issuance and purchase of treasury shares | - | ( |
) | - | - | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
| Repayment of perpetuals securities | - | - | - | - | ( |
) | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||||||
| Dividends paid on common shares | - | ( |
) | - | - | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
| Coupons on perpetual securities | - | ( |
) | - | - | - | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
| Incentive plans | - | ( |
) | - | - | - | ( |
) | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||||
| Change in ownership non-controlling interest |
- | - | - | - | - | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||
On June 30, 2026 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||
1 |
Issued capital and reserves attributable to owners of Aegon Ltd. |
| Amounts in EUR millions | Share capital |
Retained earnings |
Revaluation reserves |
Remeasurement of defined benefit plans |
Other reserves |
Other equity instruments |
Issued capital and reserves 1 |
Non- controlling interests |
Total | |||||||||||||||||||||||||||
On January 1, 2025 |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
| Net result recognized in the income statement | - | - | - | - | - | |||||||||||||||||||||||||||||||
Other comprehensive income: |
||||||||||||||||||||||||||||||||||||
Items that will not be reclassified to profit or loss: |
||||||||||||||||||||||||||||||||||||
| Gains/ (losses) on investments in equity instruments (FVOCI) | - | - | ( |
) | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
| Remeasurements of defined benefit plans | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Income tax relating to items that will not be reclassified | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
Insurance items that may be reclassified subsequently to profit or loss: |
||||||||||||||||||||||||||||||||||||
| Unrealized gains / (losses) on financial assets (FVOCI) | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Realized gains / (losses) on disposal of financial assets (FVOCI) | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Insurance finance income / (expenses) | - | - | ( |
) | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
| Reinsurance finance income / (expenses) | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Changes in cash flow hedging reserve | - | - | ( |
) | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
| Income tax relating to items that may be reclassified | - | - | ( |
) | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
Items that may be reclassified subsequently to profit or loss: |
||||||||||||||||||||||||||||||||||||
| Unrealized gains / (losses) on financial assets (FVOCI) | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Realized gains / (losses) on disposal of financial assets (FVOCI) | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Changes in cash flow hedging reserve | - | - | ( |
) | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
| Movements in foreign currency translation and net foreign investment hedging reserves | - | - | ( |
) | - | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||
| Equity movements of joint ventures | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Equity movements of associates | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
| Disposal | - | - | - | - | ( |
) | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
| Income tax relating to items that may be reclassified | - | - | ( |
) | - | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||
| Other | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
Total other comprehensive income / (loss) |
- |
( |
) |
( |
) |
- |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Total comprehensive income / (loss) |
- |
( |
) |
- |
||||||||||||||||||||||||||||||||
| Issuance and purchase of treasury shares | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
| Dividends paid on common shares | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
| Coupons on perpetual securities | - | ( |
) | - | - | - | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||
| Incentive plans | - | ( |
) | - | - | - | ( |
) | ( |
) | - | ( |
) | |||||||||||||||||||||||
On June 30, 2025 |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
1 |
Issued capital and reserves attributable to owners of Aegon Ltd. |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 17 |
|
||||
| Amounts in EUR millions | 1H 2026 |
1H 2025 3 |
||||||
Result before tax from continuing operations |
||||||||
Result before tax from discontinued operations |
||||||||
Result before tax from continuing and discontinued operations |
||||||||
Results from financial transactions |
( |
) | ( |
) | ||||
Amortization and depreciation |
( |
) | ( |
) | ||||
Impairment losses |
( |
) | ||||||
Results from (re)insurance contracts and investment contracts with discretionary participation features |
||||||||
Income from joint ventures |
( |
) | ( |
) | ||||
Income from associates |
( |
) | ( |
) | ||||
Release of cash flow hedging reserve |
( |
) | ( |
) | ||||
Other |
||||||||
Adjustments of non-cash items |
( |
) |
( |
) | ||||
Investment contracts without discretionary participation features |
||||||||
Accrued expenses and other liabilities |
||||||||
Accrued income and prepayments |
( |
) | ( |
) | ||||
Changes in accruals |
||||||||
Insurance contracts |
( |
) | ( |
) | ||||
Investment contracts with discretionary participation features |
( |
) | ( |
) | ||||
Reinsurance contracts held |
||||||||
Purchase of investments (other than money market investments) |
( |
) | ( |
) | ||||
Purchase of derivatives |
( |
) | ||||||
Disposal of investments (other than money market investments) |
||||||||
Disposal of derivatives |
( |
) | ||||||
Net change in cash collateral |
( |
) | ||||||
Net purchase of money market investments |
( |
) | ||||||
Cash flow movements on operating items not reflected in income |
( |
) |
( |
) | ||||
Tax (paid)/ received |
( |
) | ||||||
Other |
( |
) | ||||||
Net cash flows from operating activities |
( |
) | ||||||
Purchase of intangible assets (other than future servicing rights) |
( |
) | ( |
) | ||||
Purchase of equipment and real estate for own use |
( |
) | ( |
) | ||||
Acquisition of subsidiaries, net of cash |
( |
) | ||||||
Acquisition/capital contributions joint ventures and associates |
( |
) | ( |
) | ||||
Disposal of equipment |
||||||||
Disposal joint ventures and associates |
||||||||
Dividend received from joint ventures and associates |
||||||||
Net cash flows from investing activities |
||||||||
Purchase of treasury shares |
( |
) | ( |
) | ||||
Proceeds from TRUPS 1 , Subordinated borrowings and borrowings |
||||||||
Repayment of TRUPS 1 , subordinated loans and borrowings |
( |
) | ( |
) | ||||
Repayment of perpetuals securities |
( |
) | ||||||
Coupons on perpetual securities |
( |
) | ( |
) | ||||
Payment of lease liabilities |
( |
) | ( |
) | ||||
Change in ownership non-controlling interests |
( |
) | ||||||
Net cash flows from financing activities |
( |
) |
( |
) | ||||
Net increase / (decrease) in cash and cash equivalents 2 |
( |
) | ||||||
Net cash and cash equivalents at the beginning of the year |
||||||||
Effects of changes in exchange rate |
( |
) | ||||||
Net cash and cash equivalents at the end of the period |
||||||||
Cash classified as Assets held for sale |
||||||||
Cash and cash equivalents in balance sheet |
||||||||
1 |
Trust pass-through securities. |
2 |
Included in net increase / (decrease) in cash and cash equivalents are interest received EUR |
3 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| 18 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements | ||||
| • | Annual Improvements Volume 11 (issued on July 18, 2024) |
| • | Amendments to IFRS 9 and IFRS 7: Classification and Measurement of Financial Instruments (issued on May 30, 2024) |
| • | Amendments to IFRS 9 and IFRS 7: Contracts Referencing Nature-dependent Electricity (issued on December 18, 2024) |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 19 |
|
||||
1H 2026 |
Americas | United Kingdom |
Interna- tional |
Asset Manage- ment |
Holding and other activities |
Elimi- nations |
Segment total |
JVs and associates elimi- nations |
Consoli- dated |
|||||||||||||||||||||||||||
Operating result |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
| Fair value items | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
| Realized gains / (losses) on investments | ( |
) | ||||||||||||||||||||||||||||||||||
| Impairment (losses) / reversals | ( |
) | ||||||||||||||||||||||||||||||||||
Non-operating items |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||
| Other income / (charges) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Result before tax |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
| Income tax (expense) / benefit | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Net result |
( |
) |
||||||||||||||||||||||||||||||||||
Inter-segment result |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||
Revenues |
||||||||||||||||||||||||||||||||||||
| Insurance contracts: direct part. | ||||||||||||||||||||||||||||||||||||
| Insurance contracts: without direct part. | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
| Investment contracts with DPF: direct part. | ( |
) | ||||||||||||||||||||||||||||||||||
| Investment contracts with DPF: without direct part. | ( |
) | ||||||||||||||||||||||||||||||||||
Insurance revenue |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
| Interest revenue on financial instruments calculated using the effective interest method | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
| Interest income from instruments measured at FVPL | ( |
) | ||||||||||||||||||||||||||||||||||
| Other investment income | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
| Fee and commission income | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
| Other revenues | ( |
) | ||||||||||||||||||||||||||||||||||
Total revenues |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
Inter-segment revenues |
||||||||||||||||||||||||||||||||||||
| 1H 2025 | Americas | United Kingdom 1 |
Interna- tional |
Asset Manage- ment |
Holding and other activities |
Elimi- nations |
Segment total |
JVs and associates elimi- nations |
Consoli- dated |
|||||||||||||||||||||||||||
Operating result |
( |
) |
||||||||||||||||||||||||||||||||||
| Fair value items | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
| Realized gains / (losses) on investments | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||
| Impairment (losses) / reversals | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Non-operating items |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||
| Other income / (charges) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Result before tax |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
| Income tax (expense) / benefit | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Net result |
( |
) |
||||||||||||||||||||||||||||||||||
Inter-segment result |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
Revenues |
||||||||||||||||||||||||||||||||||||
| Insurance contracts: direct part. | ||||||||||||||||||||||||||||||||||||
| Insurance contracts: without direct part. | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
Insurance revenue |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
| Interest revenue on financial instruments calculated using the effective interest method | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
| Interest income from instruments measured at FVPL | ||||||||||||||||||||||||||||||||||||
| Other investment income | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
| Fee and commission income | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
| Other revenues | ( |
) | ||||||||||||||||||||||||||||||||||
Total revenues |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
Inter-segment revenues |
||||||||||||||||||||||||||||||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| 20 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 3 | ||||
Note |
1H 2026 |
1H 2025 2 |
||||||||||
Result before tax from continuing operations |
||||||||||||
Elimination of share in earnings of joint ventures and associates |
( |
) | ( |
) | ||||||||
Insurance service expenses |
4 |
|||||||||||
Net income / (expenses) on reinsurance held |
4 |
( |
) | ( |
) | |||||||
Net fair value change of financial investments at FVPL, other than derivatives |
5 |
( |
) | ( |
) | |||||||
Net fair value change of derivatives |
5 |
( |
) | |||||||||
Realized gains and losses on financial investments |
5 |
( |
) | |||||||||
Net fair value change on investments in real estate |
5 |
( |
) | |||||||||
Impairment (losses) / reversals |
5 |
( |
) | |||||||||
Insurance finance income / (expenses) |
5 |
|||||||||||
Net reinsurance finance income / (expenses) on reinsurance held |
5 |
|||||||||||
Fee and commission income |
6 |
( |
) | |||||||||
Commissions and expenses |
7 |
|||||||||||
Other income |
( |
) | ||||||||||
Other charges |
( |
) | ||||||||||
Effects related to discontinued operations |
||||||||||||
Operating result |
||||||||||||
Tax effect 1 |
( |
) | ( |
) | ||||||||
Operating result after tax |
||||||||||||
1 |
Tax effect was calculated using the respective operating segment’s statutory rate and presented on consolidated basis. |
2 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| • | Insurance service expenses are mainly driven by two items: |
° |
Assumption changes on onerous contracts amounting to a loss of EUR |
° |
Change in value of VFA products that result in (a reversal of) onerous contracts, amounting to a gain of EUR |
| • | Net income / (expenses) on reinsurance held mainly consist of assumption changes that relate to (a reversal of) underlying onerous contracts, amounting to a gain of EUR |
| • | Net fair value change of financial investments at fair value through profit or loss, other than derivatives reflects the over- or underperformance of investments and guarantees held at fair value for which the expected long-term return is included in the operating result. |
| • | Insurance finance income / (expenses) mainly relates to changes in the fair value of VFA products, amounting to a loss of EUR million), which is included in Fair value items. |
| • | Net reinsurance finance income / (expenses) on reinsurance held relate to changes in discount rates and is included in Fair value items. |
| • | Commissions and expenses, which are included in Other income / (charges), relate to items that cannot be directly allocated to a specific line of business and restructuring charges. |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 21 |
|
||||
June 30, 2026 |
Americas | United Kingdom |
|
International | Asset Management |
|
Holding and other activities |
|
Total | |||||||||||||||
| Shares | - | - | ||||||||||||||||||||||
| Debt securities | - | - | ||||||||||||||||||||||
| Unconsolidated investment funds | - | - | - | |||||||||||||||||||||
| Loans | - | - | ||||||||||||||||||||||
| Other financial assets | - | - | ||||||||||||||||||||||
| Investments in real estate | - | - | - | |||||||||||||||||||||
Total investments on balance sheet |
- |
|||||||||||||||||||||||
Off-balance sheet investments third parties |
- | - | ||||||||||||||||||||||
Total revenue-generating investments |
- |
|||||||||||||||||||||||
Investments |
||||||||||||||||||||||||
Financial assets measured at FVOCI |
||||||||||||||||||||||||
| - Backing insurance contracts without direct part. | - | - | - | |||||||||||||||||||||
| - Non-insurance related assets |
- | - | ||||||||||||||||||||||
Financial assets measured at FVPL |
||||||||||||||||||||||||
| - Backing direct part. insurance contracts | - | - | - | |||||||||||||||||||||
| - Backing insurance contracts without direct part. | - | - | - | |||||||||||||||||||||
| - Non-insurance related assets |
- | - | ||||||||||||||||||||||
Financial assets measured at amortized cost |
- | |||||||||||||||||||||||
| Investments in real estate | - | - | - | |||||||||||||||||||||
Total investments on balance sheet |
- |
|||||||||||||||||||||||
| Investments in joint ventures | - | - | - | |||||||||||||||||||||
| Investments in associates | - | - | ||||||||||||||||||||||
| Other assets 1 |
||||||||||||||||||||||||
| Assets held for sale | - | - | - | - | ||||||||||||||||||||
Consolidated total assets |
||||||||||||||||||||||||
1 |
Other assets total eliminates intercompany transactions of EUR |
December 31, 2025 |
Americas | United Kingdom |
|
International | Asset Management |
|
Holding and other activities |
|
Total | |||||||||||||||
Shares |
- | |||||||||||||||||||||||
| Debt securities | - | |||||||||||||||||||||||
| Unconsolidated investment funds | - | - | ||||||||||||||||||||||
| Loans | - | |||||||||||||||||||||||
| Other financial assets | - | |||||||||||||||||||||||
| Investments in real estate | - | - | ||||||||||||||||||||||
Total investments on balance sheet |
||||||||||||||||||||||||
Off-balance sheet investments third parties |
- | |||||||||||||||||||||||
Total revenue-generating investments |
||||||||||||||||||||||||
Investments |
||||||||||||||||||||||||
Financial assets measured at FVOCI |
||||||||||||||||||||||||
| - Backing insurance contracts without direct part. | - | - | - | |||||||||||||||||||||
| - Non-insurance related assets |
- | - | ||||||||||||||||||||||
Financial assets measured at FVPL |
||||||||||||||||||||||||
| - Backing direct part. insurance contracts | - | - | ||||||||||||||||||||||
| - Backing insurance contracts without direct part. | - | - | ||||||||||||||||||||||
| - Backing direct part. investment contracts | - | - | - | - | ||||||||||||||||||||
| - Non-insurance related assets |
- | |||||||||||||||||||||||
Financial assets measured at amortized cost |
- | |||||||||||||||||||||||
| Investments in real estate | - | - | ||||||||||||||||||||||
Total investments on balance sheet |
||||||||||||||||||||||||
| Investments in joint ventures | - | - | - | |||||||||||||||||||||
| Investments in associates | - | - | ||||||||||||||||||||||
| Other assets 1 |
||||||||||||||||||||||||
Consolidated total assets |
||||||||||||||||||||||||
1 |
Other assets total eliminates intercompany transactions of EUR |
| 22 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 4 | ||||
| Americas | United Kingdom |
International | Eliminations | Total | ||||||||||||||||
June 30, 2026 |
||||||||||||||||||||
Insurance contracts |
||||||||||||||||||||
Direct participation contracts |
- | - | ||||||||||||||||||
Without direct participation contracts |
- | ( |
) | |||||||||||||||||
Contracts measured under the PAA |
- | - | - | |||||||||||||||||
Investment contracts with DPF |
||||||||||||||||||||
Without direct participation contracts |
- | - | - | |||||||||||||||||
Insurance contracts and investment contracts with DPF |
- |
( |
) |
|||||||||||||||||
Reinsurance contracts held |
- | ( |
) | |||||||||||||||||
December 31, 2025 |
||||||||||||||||||||
Insurance contracts |
||||||||||||||||||||
Direct participation contracts |
- | |||||||||||||||||||
Without direct participation contracts |
( |
) | ||||||||||||||||||
Contracts measured under the PAA |
- | - | - | |||||||||||||||||
Investment contracts with DPF |
||||||||||||||||||||
Direct participation contracts |
- | - | - | |||||||||||||||||
Without direct participation contracts |
- | - | - | |||||||||||||||||
Insurance contracts and investment contracts with DPF |
( |
) |
||||||||||||||||||
Reinsurance contracts held |
( |
) | ( |
) | ||||||||||||||||
1H 2026 |
1H 2025 | 1 | ||||||
Insurance revenue |
||||||||
Expected insurance claims and expenses |
||||||||
Earnings released from CSM |
||||||||
Release of risk adjustment |
||||||||
Recovery of acquisition cash flows |
||||||||
Other |
||||||||
Contracts measured under Non-PAA |
||||||||
Contracts measured under the PAA |
||||||||
Total Insurance revenue |
||||||||
Insurance service expenses |
||||||||
Incurred claims and expenses |
( |
) | ( |
) | ||||
Onerous contract losses (and reversals) |
( |
) | ( |
) | ||||
Amortization of acquisition cash flows |
( |
) | ( |
) | ||||
Contracts measured under Non-PAA |
( |
) |
( |
) | ||||
Contracts measured under PAA |
( |
) | ( |
) | ||||
Total Insurance service expenses |
( |
) |
( |
) | ||||
Net income / (expenses) on reinsurance held |
||||||||
Assumption changes that adjust underlying onerous contracts |
||||||||
Experience adjustments that adjust underlying onerous contracts |
||||||||
CSM recognized for service received |
( |
) | ( |
) | ||||
Release of risk adjustment |
( |
) | ( |
) | ||||
Experience adjustments on current service |
( |
) | ||||||
Gain on retrospective reinsurance for incurred claims |
||||||||
Reversals of loss recovery component from onerous underlying contracts |
||||||||
Contracts measured under Non-PAA |
||||||||
Contracts measured under PAA |
||||||||
Net income / (expenses) on reinsurance held |
||||||||
Insurance service result |
||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 23 |
|
||||
Revenue recognized on insurance contracts in-force |
1H 2026 |
1H 2025 1 |
||||||
Transitioned under the modified retrospective approach |
||||||||
Transitioned under the fair value approach |
||||||||
Other contracts |
||||||||
Total revenue recognized on insurance contracts |
||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
1H 2026 |
1H 2025 1 |
|||||||
Insurance net investment result |
||||||||
Other net investment result |
||||||||
Financing net investment result |
( |
) | ( |
) | ||||
Total net investment result |
||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| Insurance contracts | 1H 2026 |
|||||||||||
| Direct part. | Without direct part. | Total | 1 | |||||||||
Insurance investment return |
||||||||||||
| Interest revenue on financial instruments calculated using the effective interest method | - | |||||||||||
Interest income from instruments measured at FVPL |
- | |||||||||||
Other investment income |
- | |||||||||||
Results from financial transactions |
||||||||||||
Impairment (losses) / reversals |
- | |||||||||||
| Interest expenses | - | ( |
) | ( |
) | |||||||
Profit or loss impacts |
||||||||||||
Unrealized gains / (losses) on financial assets (FVOCI) |
- | ( |
) | ( |
) | |||||||
| Realized gains / (losses) on disposal of financial assets (FVOCI) | - | ( |
) | ( |
) | |||||||
OCI impacts |
- |
( |
) |
( |
) | |||||||
Total insurance investment return |
||||||||||||
Insurance finance income / (expenses) – General model |
||||||||||||
Interest accreted to insurance contracts |
- | ( |
) | ( |
) | |||||||
Interest rate and other financial assumption changes |
- | ( |
) | ( |
) | |||||||
| Revaluation of changes in non-financial assumptions and experience adjustments to current interest rates |
- | |||||||||||
Insurance finance income / (expenses) – Variable fee approach |
||||||||||||
| Change in fair value of underlying assets | ( |
) | - | ( |
) | |||||||
| Change in fulfillment value - risk mitigation option | - | |||||||||||
Total insurance finance income / (expenses) |
( |
) |
( |
) |
( |
) | ||||||
Represented by: |
||||||||||||
Amounts recognized in profit or loss |
( |
) | ( |
) | ( |
) | ||||||
Amounts recognized in OCI |
||||||||||||
Reinsurance finance income / (expenses) on reinsurance held |
||||||||||||
Interest accreted to reinsurance contracts |
- | |||||||||||
Interest rate and other financial assumption changes |
- | ( |
) | ( |
) | |||||||
| Revaluation of changes in non-financial assumptions and experience adjustments to current interest rates |
- | ( |
) | ( |
) | |||||||
Changes in risk of non-performance of reinsurers |
- | ( |
) | ( |
) | |||||||
Total reinsurance finance income / (expenses) on reinsurance held |
- |
|||||||||||
Represented by: |
||||||||||||
Amounts recognized in profit or loss |
- | |||||||||||
Amounts recognized in OCI |
- | ( |
) | ( |
) | |||||||
Insurance net investment result |
( |
) |
( |
) |
( |
) | ||||||
Represented by: |
||||||||||||
Amounts recognized in profit or loss |
( |
) | ||||||||||
Amounts recognized in OCI |
( |
) | ( |
) | ||||||||
1 |
Investment contracts with DPF - Without direct part. includes EUR ( |
| 24 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 6 | ||||
| Insurance contracts | 1 |
|||||||||||
| Direct part. | Without direct part. | Total | ||||||||||
Insurance investment return |
||||||||||||
| Interest revenue on financial instruments calculated using the effective interest method | - | |||||||||||
Interest income from instruments measured at FVPL |
- | |||||||||||
Other investment income |
- | |||||||||||
Results from financial transactions |
||||||||||||
Impairment (losses) / reversals |
- | ( |
) | ( |
) | |||||||
| Interest expenses | - | ( |
) | ( |
) | |||||||
Profit or loss impacts |
||||||||||||
Gains / (losses) on investments in equity instruments (FVOCI) |
- | ( |
) | ( |
) | |||||||
Unrealized gains / (losses) on financial assets (FVOCI) |
- | |||||||||||
| Realized gains / (losses) on disposal of financial assets (FVOCI) | - | |||||||||||
OCI impacts |
- |
|||||||||||
Total insurance investment return |
||||||||||||
Insurance finance income / (expenses) – General model |
||||||||||||
Interest accreted to insurance contracts |
- | ( |
) | ( |
) | |||||||
Interest rate and other financial assumption changes |
- | ( |
) | ( |
) | |||||||
| Revaluation of changes in non-financial assumptions and experience adjustments to current interest rates |
- | |||||||||||
Insurance finance income / (expenses) – Variable fee approach |
||||||||||||
| Change in fair value of underlying assets | ( |
) | - | ( |
) | |||||||
| Change in fulfillment value - risk mitigation option | - | |||||||||||
Total insurance finance income / (expenses) |
( |
) |
( |
) |
( |
) | ||||||
Represented by: |
||||||||||||
Amounts recognized in profit or loss |
( |
) | ( |
) | ( |
) | ||||||
Amounts recognized in OCI |
( |
) | ( |
) | ||||||||
Reinsurance finance income / (expenses) on reinsurance held |
||||||||||||
Interest accreted to reinsurance contracts |
- | |||||||||||
Interest rate and other financial assumption changes |
- | |||||||||||
| Revaluation of changes in non-financial assumptions and experience adjustments to current interest rates |
- | ( |
) | ( |
) | |||||||
Changes in risk of non-performance of reinsurers |
- | |||||||||||
Total reinsurance finance income / (expenses) on reinsurance held |
- |
|||||||||||
Represented by: |
||||||||||||
Amounts recognized in profit or loss |
- | |||||||||||
Amounts recognized in OCI |
- | |||||||||||
Insurance net investment result |
||||||||||||
Represented by: |
||||||||||||
Amounts recognized in profit or loss |
||||||||||||
Amounts recognized in OCI |
||||||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
1H 2026 |
1H 2025 1 |
|||||||||||||||
| Insurance | Non-insurance |
Insurance | Non-insurance |
|||||||||||||
Fair value gains and losses derivatives |
( |
) | ||||||||||||||
Fair value changes of financial assets at FVPL |
||||||||||||||||
Other |
( |
) | ( |
) | ||||||||||||
Results from financial transactions |
||||||||||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
1H 2026 |
1H 2025 1 |
|||||||
Fee from asset management and insurance distribution |
||||||||
Other fee and commission income |
||||||||
Fee and commission income |
||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 25 |
|
||||
1H 2026 |
1H 2025 1 |
|||||||||||||||
| Insurance | Non-Insurance |
Insurance | Non-Insurance |
|||||||||||||
Policyholder claims and benefits |
( |
) | - | ( |
) | - | ||||||||||
Onerous contract losses (and reversals) |
( |
) | - | ( |
) | - | ||||||||||
Commissions |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Handling and clearing fees |
- | ( |
) | - | ( |
) | ||||||||||
Right-of-use |
- | ( |
) | - | ( |
) | ||||||||||
Employee expenses |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Administration expenses |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Deferred transaction expenses |
- | - | ||||||||||||||
Amortization of deferred expenses |
- | ( |
) | - | ( |
) | ||||||||||
Amortization of other intangibles |
- | ( |
) | - | ( |
) | ||||||||||
Total |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||
Amounts attributed to acquisition cash flows |
- | - | ||||||||||||||
Amortization of acquisition cash flows |
( |
) | - | ( |
) | - | ||||||||||
Amortization of acquisition cash flows PAA |
( |
) | - | ( |
) | - | ||||||||||
Total other operating expenses |
( |
) |
( |
) |
( |
( |
||||||||||
1 |
1H 2025 figures are restated as Aegon UK is classified as discontinued operations. |
| Insurance contracts | Investment contracts with DPF |
Non-Insurance related |
Total |
|||||||||||||||||
June 30, 2026 |
Direct part. | Without direct part. |
Direct part. | |||||||||||||||||
FVOCI – with recycling |
- | - | ||||||||||||||||||
FVOCI – no recycling |
- | - | ||||||||||||||||||
Amortized cost |
- | - | ||||||||||||||||||
FVPL – designated |
- | |||||||||||||||||||
FVPL – mandatory |
- | - | ||||||||||||||||||
Total financial assets (excl. derivatives) |
- |
|||||||||||||||||||
Investments in real estate |
- | - | - | |||||||||||||||||
Total investments |
- |
|||||||||||||||||||
December 31, 2025 |
||||||||||||||||||||
| FVOCI – with recycling | - | - | ||||||||||||||||||
FVOCI – no recycling |
- | - | ||||||||||||||||||
Amortized cost |
- | - | ||||||||||||||||||
FVPL – designated |
||||||||||||||||||||
FVPL – mandatory |
- | - | ||||||||||||||||||
Total financial assets (excl. derivatives) |
||||||||||||||||||||
| Investments in real estate | ||||||||||||||||||||
Total investments |
||||||||||||||||||||
| 26 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 10 | ||||
Investments - Aegon risk June 30, 2026 |
FVOCI (recycling) |
FVOCI (no recycling) |
Amortized cost |
FVPL (designated) |
FVPL (mandatory) |
Total |
Fair value | |||||||||||||||||||||
Shares |
- | - | - | |||||||||||||||||||||||||
Debt securities |
- | |||||||||||||||||||||||||||
Money market and other short-term investments |
- | - | ||||||||||||||||||||||||||
Deposits with financial institutions |
- | - | - | - | ||||||||||||||||||||||||
Loans |
- | - | - | |||||||||||||||||||||||||
Other |
- | - | ||||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||||
December 31, 2025 |
||||||||||||||||||||||||||||
Shares |
- | - | - | |||||||||||||||||||||||||
Debt securities |
- | |||||||||||||||||||||||||||
Money market and other short-term investments |
- | - | ||||||||||||||||||||||||||
Deposits with financial institutions |
- | - | - | - | ||||||||||||||||||||||||
Loans |
- | - | - | |||||||||||||||||||||||||
Other |
- | - | ||||||||||||||||||||||||||
Total |
||||||||||||||||||||||||||||
Investments - Policyholder risk |
June 30, 2026 |
December 31, 2025 | ||||||
Shares |
||||||||
Debt securities |
||||||||
Money market and other short-term investments |
- | |||||||
Unconsolidated investment funds |
||||||||
Deposits with financial institutions |
||||||||
Total |
||||||||
| Fair value hierarchy | ||||||||||||||||
June 30, 2026 |
Level I | Level II | Level III | Total | ||||||||||||
Shares |
- | |||||||||||||||
Debt securities |
||||||||||||||||
Money market and other short-term investments |
||||||||||||||||
Other investments at fair value |
- | - | ||||||||||||||
Total financial assets measured at FVOCI |
||||||||||||||||
Shares |
||||||||||||||||
Debt securities |
||||||||||||||||
Money market and other short-term investments |
- | - | ||||||||||||||
Loans |
- | - | |
|||||||||||||
Other investments at fair value |
||||||||||||||||
Derivatives |
- | |||||||||||||||
Investments - Policyholder risk |
||||||||||||||||
Total financial assets measured at FVPL |
||||||||||||||||
Total financial assets measured at fair value |
||||||||||||||||
Investment contracts without DPF - Policyholder risk |
- | - | ||||||||||||||
Derivatives |
- | |||||||||||||||
Total financial liabilities measured at fair value |
- |
|||||||||||||||
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 27 |
|
||||
| Fair value hierarchy | ||||||||||||||||
| December 31, 2025 | Level I | Level II | Level III | Total | ||||||||||||
Shares |
- | |||||||||||||||
Debt securities |
||||||||||||||||
Money market and other short-term investments |
- | |||||||||||||||
Other investments at fair value |
- | |||||||||||||||
Total financial assets measured at FVOCI |
||||||||||||||||
Shares |
||||||||||||||||
Debt securities |
||||||||||||||||
Money market and other short-term investments |
- | |||||||||||||||
Loans |
- | - | ||||||||||||||
Other investments at fair value |
|
|||||||||||||||
Derivatives |
||||||||||||||||
Investments - Policyholder risk |
|
|||||||||||||||
Total financial assets measured at FVPL |
||||||||||||||||
Total financial assets measured at fair value |
||||||||||||||||
Investment contracts without DPF - Policyholder risk |
- | - | ||||||||||||||
Derivatives |
- | |||||||||||||||
Total financial liabilities measured at fair value |
- |
|||||||||||||||
On January 1, 2026 |
Total gains / (losses) in income statement 1 |
Total gains / (losses) in OCI 2 |
Purch- ases |
Sales |
Settle- ments |
Net ex- change difference |
Trans- fers from levels I and II |
Transfers to levels I and II |
Transfers to disposal groups |
On June 30, 2026 |
Total URGL for the period 3 |
|||||||||||||||||||||||||||||||||||||
Shares |
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
Debt securities |
( |
) | ( |
) | ( |
) | - | - | ||||||||||||||||||||||||||||||||||||||||
| Money markets and other short-term investments | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Other investments at fair value | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||
Total FVOCI |
( |
) |
( |
) |
( |
) |
- |
- |
||||||||||||||||||||||||||||||||||||||||
Shares |
( |
) | - | ( |
) | - | - | - | ( |
) | ||||||||||||||||||||||||||||||||||||||
Debt securities |
- | ( |
) | ( |
) | - | - | ( |
) | |||||||||||||||||||||||||||||||||||||||
Loans |
( |
) | - | - | - | - | - | - | ( |
) | ||||||||||||||||||||||||||||||||||||||
Other investments |
( |
) | - | ( |
) | - | - | - | - | ( |
) | |||||||||||||||||||||||||||||||||||||
Derivatives |
- | - | - | - | - | - | - | ( |
) | - | - | |||||||||||||||||||||||||||||||||||||
Investments - |
||||||||||||||||||||||||||||||||||||||||||||||||
| Policyholder risk | - | ( |
) | - | - | - | ( |
) | - | |||||||||||||||||||||||||||||||||||||||
Total FVPL |
( |
) |
- |
( |
) |
( |
) |
- |
( |
) |
( |
) | ||||||||||||||||||||||||||||||||||||
Total financial assets |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||||||||||||
On January 1, 2025 |
Disposal of a business |
Total gains / (losses) in income statement 1 |
Total gains / (losses) in OCI 2 |
Purch- ases |
Sales | Settle- ments |
Net ex- change differ- ence |
Trans- fers from levels I and II |
Trans- fers to levels I and II |
On December 31, 2025 |
Total URGL for the period 3 |
|||||||||||||||||||||||||||||||||||||
| Shares | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| Debt securities | - | ( |
) | ( |
) | ( |
) | ( |
) | - | ||||||||||||||||||||||||||||||||||||||
| Other | - | - | - | ( |
) | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||
Total FVOCI |
- |
( |
) |
( |
) |
( |
) |
( |
) |
- |
||||||||||||||||||||||||||||||||||||||
| Shares | - | - | ( |
) | - | ( |
) | - | - | |||||||||||||||||||||||||||||||||||||||
| Debt securities | - | - | - | ( |
) | ( |
) | ( |
) | ( |
) | - | ||||||||||||||||||||||||||||||||||||
| Loans | - | - | ( |
) | - | ( |
) | - | - | |||||||||||||||||||||||||||||||||||||||
| Other investments | - | ( |
) | - | ( |
) | - | ( |
) | - | - | |||||||||||||||||||||||||||||||||||||
| Derivatives | - | - | - | - | ( |
) | - | - | - | - | ( |
) | ||||||||||||||||||||||||||||||||||||
| Investments - Policyholder risk | ( |
) | ( |
) | - | ( |
) | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||||||||||
Total FVPL |
( |
) |
( |
) |
- |
( |
) |
( |
) |
( |
) |
( |
) |
|||||||||||||||||||||||||||||||||||
Total financial assets |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||||||
1 |
Includes impairments and movements related to fair value hedges. Gains and losses are recorded in the line item Results from financial transactions of the income statement. |
2 |
Total gains and losses are recorded in line items Unrealized gains / (losses) on financial assets measured at FVOCI and Realized gains / (losses) on disposal of financial assets measured at FVOCI of the statement of comprehensive income. |
3 |
Total unrealized gains / (losses) for the period recorded in the P&L during which the financial instrument was in Level III. |
| 28 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 11 | ||||
On June 30, 2026 |
On December 31, 2025 | |||||||||||||||
| Carrying amount |
Total estimated fair value |
Carrying amount |
Total estimated fair value |
|||||||||||||
Assets |
||||||||||||||||
Debt securities - held at amortized cost |
||||||||||||||||
Loans - held at amortized cost |
||||||||||||||||
Deposits with financial institutions - held at amortized cost |
||||||||||||||||
Liabilities |
||||||||||||||||
Subordinated borrowings - held at amortized cost |
||||||||||||||||
Trust pass-through securities - held at amortized cost |
||||||||||||||||
Borrowings - held at amortized cost |
||||||||||||||||
Investment contracts - held at amortized cost |
||||||||||||||||
June 30, 2026 |
December 31, 2025 | |||||||
Share capital - par value |
||||||||
Share premium |
||||||||
Total share capital |
||||||||
Share capital - par value |
||||||||
Balance on January 1 |
||||||||
Shares withdrawn |
( |
) | ||||||
Closing balance |
||||||||
| Interim fi nan cial information for the six-mo nth period ended June 30, 2026 - Unaudited | 29 |
|
||||
Continuing and discontinued operations |
1H 2026 |
1H 2025 | ||||||
Net result attributable to owners of Aegon Ltd. |
||||||||
Coupons on perpetual securities |
( |
) | ( |
) | ||||
Net result attributable to owners for basic earnings per share calculation |
||||||||
Net result attributable to common shareholders |
||||||||
Net result attributable to common shareholders B |
||||||||
Weighted average number of common shares outstanding (in millions) |
||||||||
Weighted average number of common shares B outstanding (in millions) |
||||||||
Basic earnings per common share (EUR per share) |
||||||||
Basic earnings per common share B (EUR per share) |
||||||||
EUR per common share | ||||||
| Year | Interim | Final | Total | |||
2026 |
1 |
n.a. | n.a. | |||
2025 |
2 |
|||||
1 |
Proposed. |
2 |
Approved by AGM on June 10, 2026. |
| 30 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 12 | ||||
Investments FVOCI |
Real estate held for own use |
Cash flow hedging reserve |
Insurance contracts |
Investment contracts with DPF |
Reinsurance contracts held |
Total | ||||||||||||||||||||||
On January 1, 2026 |
( |
) |
- |
( |
) |
( |
) | |||||||||||||||||||||
Gross revaluation |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
| Net (gains) / losses transferred to income statement | ( |
) | ( |
) | - | ( |
) | |||||||||||||||||||||
| Movements in foreign currency translation and net foreign investment hedging reserves | ( |
) | - | ( |
) | ( |
) | |||||||||||||||||||||
Tax effect |
( |
) | ( |
) | - | |||||||||||||||||||||||
On June 30, 2026 |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
On January 1, 2025 |
( |
) |
- |
( |
) |
( |
) | |||||||||||||||||||||
Gross revaluation |
( |
) | ( |
) | - | |||||||||||||||||||||||
| Net (gains) / losses transferred to income statement | ( |
) | - | |||||||||||||||||||||||||
| Movements in foreign currency translation and net foreign investment hedging reserves | ( |
) | ( |
) | ( |
) | - | |||||||||||||||||||||
Tax effect |
( |
) | - | ( |
) | ( |
) | |||||||||||||||||||||
Disposal of group assets |
( |
) | - | ( |
) | |||||||||||||||||||||||
Other |
( |
) | - | ( |
) | |||||||||||||||||||||||
On December 31, 2025 |
( |
) |
- |
( |
) |
( |
) | |||||||||||||||||||||
June 30, 2026 |
December 31, 2025 | |||||||
Shares |
||||||||
Debt securities |
( |
) | ( |
) | ||||
Money market and other short-term investments |
( |
) | ( |
) | ||||
Revaluation reserve for investments measured at FVOCI |
( |
) |
( |
) | ||||
June 30, 2026 |
December 31, 2025 | |||||||||||||||||||||||
By measurement model |
Non-PAA | PAA | Total | Non-PAA | PAA | Total | ||||||||||||||||||
Insurance contract assets |
||||||||||||||||||||||||
Insurance contract liabilities |
||||||||||||||||||||||||
Insurance contracts net balance |
||||||||||||||||||||||||
Reinsurance contract assets |
||||||||||||||||||||||||
Reinsurance contract liabilities |
||||||||||||||||||||||||
Reinsurance contracts net balance |
||||||||||||||||||||||||
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 31 |
|
||||
| • | For insurance contracts and investment contracts with DPF - Liability for remaining coverage excluding loss component (LFRC), Loss component (LC) and Liability for incurred claims (LFIC) |
| • | For reinsurance contracts held - Asset for remaining coverage excluding loss recovery component (AFRC), Loss recovery component (LRC) and Asset for incurred claims (AFIC). |
1H 2026 |
FY 2025 |
|||||||||||||||||||||||||||||||
Insurance contracts (Non-PAA) - by type |
LFRC |
LC |
LFIC |
Total |
LFRC |
LC |
LFIC |
Total |
||||||||||||||||||||||||
Opening assets |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||
Opening liabilities |
||||||||||||||||||||||||||||||||
Net opening balance |
||||||||||||||||||||||||||||||||
Insurance revenue |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Incurred claims and expenses |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Amortization of acquisition cash flows |
||||||||||||||||||||||||||||||||
Onerous contract losses (and reversals) |
||||||||||||||||||||||||||||||||
Adjustments for incurred claims |
||||||||||||||||||||||||||||||||
Insurance service expenses |
||||||||||||||||||||||||||||||||
Investment components |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Insurance service result |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Insurance finance (income) / expenses |
||||||||||||||||||||||||||||||||
Cash flows |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||
Disposal of a business |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Transfers to disposal groups |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||
Transfer (to)/from other headings |
( |
) |
||||||||||||||||||||||||||||||
Net exchange differences |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Net closing balance |
||||||||||||||||||||||||||||||||
Closing assets |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||
Closing liabilities |
||||||||||||||||||||||||||||||||
1H 2026 |
FY 2025 |
|||||||||||||||||||||||||||||||
Reinsurance contracts (Non-PAA) - by type |
AFRC |
LRC |
AFIC |
Total |
AFRC |
LRC |
AFIC |
Total |
||||||||||||||||||||||||
Opening assets |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Opening liabilities |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Net opening balance |
( |
) |
||||||||||||||||||||||||||||||
Net expenses from reinsurance contracts |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Other reinsurance finance income / (expenses) |
||||||||||||||||||||||||||||||||
Effect of reinsurer default risk changes |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Total changes in the profit or loss and OCI |
( |
) |
||||||||||||||||||||||||||||||
Cash flows |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||
Transfers to disposal groups |
||||||||||||||||||||||||||||||||
Net exchange differences |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Net closing balance |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Closing assets |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Closing liabilities |
||||||||||||||||||||||||||||||||
| 32 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 12 | ||||
1H 2026 |
FY 2025 |
|||||||||||||||||||||||||||||||
Investment contracts with DPF - by type |
LFRC |
LC |
LFIC |
Total |
LFRC |
LC |
LFIC |
Total |
||||||||||||||||||||||||
Opening assets |
||||||||||||||||||||||||||||||||
Opening liabilities |
||||||||||||||||||||||||||||||||
Net opening balance |
||||||||||||||||||||||||||||||||
Insurance revenue |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Incurred claims and expenses |
||||||||||||||||||||||||||||||||
Onerous contract losses (and reversals) |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Insurance service expenses |
( |
) |
||||||||||||||||||||||||||||||
Investment components |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Insurance service result |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||
Insurance finance (income) / expenses |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Cash flows |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Transfers to disposal groups |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||
Net exchange differences |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Net closing balance |
||||||||||||||||||||||||||||||||
Closing assets |
||||||||||||||||||||||||||||||||
Closing liabilities |
||||||||||||||||||||||||||||||||
1H 2026 |
FY 2025 |
|||||||||||||||||||||||||||||||
Insurance contracts (Non-PAA) - by component |
BEL |
RA |
CSM |
Total |
BEL |
RA |
CSM |
Total |
||||||||||||||||||||||||
Opening assets |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||
Opening liabilities |
||||||||||||||||||||||||||||||||
Net opening balance |
||||||||||||||||||||||||||||||||
Changes in estimates that adjust CSM |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||
Changes in estimates that adjust onerous contracts |
||||||||||||||||||||||||||||||||
New contracts issued – non-onerous |
( |
) |
( |
) |
||||||||||||||||||||||||||||
New contracts issued – onerous |
||||||||||||||||||||||||||||||||
Changes that relate to future service |
( |
) |
||||||||||||||||||||||||||||||
Earnings released from CSM |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Release of risk adjustment |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Experience adjustments on current service |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Revenue from policyholder tax expenses incurred |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Changes that relate to current service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Experience adjustments on incurred claims |
||||||||||||||||||||||||||||||||
Changes that relate to past service |
||||||||||||||||||||||||||||||||
Insurance service result |
( |
) |
||||||||||||||||||||||||||||||
General model |
||||||||||||||||||||||||||||||||
Interest accreted to insurance contracts |
||||||||||||||||||||||||||||||||
Interest rate and other financial assumption changes |
( |
) |
||||||||||||||||||||||||||||||
Revaluation of changes in non-financial assumptions and experience adjustments to current interest rates |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||
Variable fee approach |
||||||||||||||||||||||||||||||||
Change in fair value of the underlying assets |
||||||||||||||||||||||||||||||||
Change in fulfilment value - risk mitigation option |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Insurance finance (income) / expenses |
||||||||||||||||||||||||||||||||
Premiums received |
||||||||||||||||||||||||||||||||
Claims, benefits and expenses paid |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Acquisition costs paid |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Other |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Cash flows |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Disposal of a business |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Transfers to disposal groups |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||
Other movements |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
Net exchange differences |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Net closing balance |
||||||||||||||||||||||||||||||||
Closing assets |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||
Closing liabilities |
||||||||||||||||||||||||||||||||
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 33 |
|
||||
1H 2026 |
FY 2025 |
|||||||||||||||||||||||||||||||
Reinsurance contracts (Non-PAA) - by component |
BEL |
RA |
CSM |
Total |
BEL |
RA |
CSM |
Total |
||||||||||||||||||||||||
Opening assets |
||||||||||||||||||||||||||||||||
Opening liabilities |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||
Net opening balance |
||||||||||||||||||||||||||||||||
Changes in estimates that adjust CSM |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||
Changes in estimates that adjust underlying onerous contracts |
( |
) |
( |
) |
||||||||||||||||||||||||||||
New reinsurance contracts recognized |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Reversals of loss recovery component |
||||||||||||||||||||||||||||||||
Changes that relate to future service |
||||||||||||||||||||||||||||||||
CSM recognized for service received |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Release of risk adjustment |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Experience adjustment on current service |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Changes that relate to current service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||
Net income/ (expenses) on reinsurance held |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Reinsurance finance income / (expenses) |
( |
) |
||||||||||||||||||||||||||||||
Premiums paid (net of commission) |
||||||||||||||||||||||||||||||||
Amounts received |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Other |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Cash flows |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Transfers to disposal groups |
( |
) |
||||||||||||||||||||||||||||||
Net exchange difference |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Net closing balance |
||||||||||||||||||||||||||||||||
Closing assets |
||||||||||||||||||||||||||||||||
Closing liabilities |
( |
) |
( |
) |
||||||||||||||||||||||||||||
1H 2026 |
FY 2025 |
|||||||||||||||||||||||||||||||
Investment contracts with DPF - by component |
BEL |
RA |
CSM |
Total |
BEL |
RA |
CSM |
Total |
||||||||||||||||||||||||
Opening assets |
||||||||||||||||||||||||||||||||
Opening liabilities |
||||||||||||||||||||||||||||||||
Net opening balance |
||||||||||||||||||||||||||||||||
Changes in estimates that adjust CSM |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||
Changes in estimates that adjust onerous contracts |
( |
) |
( |
) |
||||||||||||||||||||||||||||
New contracts issued – non-onerous |
( |
) |
||||||||||||||||||||||||||||||
Changes that relate to future service |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||
Earnings released from CSM |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Release of risk adjustment |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Experience adjustments on current service |
||||||||||||||||||||||||||||||||
Changes that relate to current service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
Insurance service result |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
General model |
||||||||||||||||||||||||||||||||
Changes in interest rates and other financial assumptions |
||||||||||||||||||||||||||||||||
Variable fee approach |
||||||||||||||||||||||||||||||||
Change in fair value of the underlying assets |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Insurance finance (income) / expenses |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Premiums received |
||||||||||||||||||||||||||||||||
Claims, benefits and expenses paid |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Acquisition costs paid |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Other |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Cash flows |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Transfers to disposal groups |
( |
) |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||
Net exchange differences |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Net closing balance |
||||||||||||||||||||||||||||||||
Closing assets |
||||||||||||||||||||||||||||||||
Closing liabilities |
||||||||||||||||||||||||||||||||
| 34 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 12 | ||||
| Insurance contracts | Reinsurance contracts held | Investment contracts with DPF | ||||||||||||||||||||||||||||||||||||||||||||||
| MRA | FVA | Other | Total | MRA | FVA | Other | Total | MRA | FVA | Other | Total | |||||||||||||||||||||||||||||||||||||
On January 1, 2026 |
||||||||||||||||||||||||||||||||||||||||||||||||
Changes in estimates that adjust CSM |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||
| Changes in estimates that adjust onerous contracts | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||
New contracts recognized |
||||||||||||||||||||||||||||||||||||||||||||||||
Earnings released from CSM |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
Insurance finance (income) / expenses |
( |
) | ||||||||||||||||||||||||||||||||||||||||||||||
Net exchange differences |
||||||||||||||||||||||||||||||||||||||||||||||||
Transfers to disposal groups |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||
On June 30, 2026 |
||||||||||||||||||||||||||||||||||||||||||||||||
On January 1, 2025 |
- |
- |
- |
|||||||||||||||||||||||||||||||||||||||||||||
Changes in estimates that adjust CSM |
( |
) | - | - | - | |||||||||||||||||||||||||||||||||||||||||||
| Changes in estimates that adjust onerous contracts | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
New contracts recognized |
- | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
Earnings released from CSM |
( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | ( |
) | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||||
Insurance finance (income) / expenses |
- | ( |
) | ( |
) | - | - | - | - | |||||||||||||||||||||||||||||||||||||||
Net exchange differences |
( |
) | ( |
) | ( |
) | ( |
) | - | ( |
) | ( |
) | ( |
) | - | ( |
) | - | ( |
) | |||||||||||||||||||||||||||
On December 31, 2025 |
- |
- |
- |
|||||||||||||||||||||||||||||||||||||||||||||
June 30, 2026 |
December 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||
Risk-free yield curves (%) |
1 year |
5 years |
10 years |
15 years |
20 years |
30 years |
1 year |
5 years |
10 years |
15 years |
20 years |
30 years |
||||||||||||||||||||||||||||||||||||
GBP |
||||||||||||||||||||||||||||||||||||||||||||||||
USD |
||||||||||||||||||||||||||||||||||||||||||||||||
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 35 |
|
||||
June 30, 2026 |
December 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||
ILP per portfolio (%) |
Country | 1 year |
5 years |
10 years |
15 years |
20 years |
30 years |
1 year |
5 years |
10 years |
15 years |
20 years |
30 years |
|||||||||||||||||||||||||||||||||||||
Fixed Deferred Annuity |
US | |||||||||||||||||||||||||||||||||||||||||||||||||
Indexed Universal Life |
US | |||||||||||||||||||||||||||||||||||||||||||||||||
Long-Term Care |
US | |||||||||||||||||||||||||||||||||||||||||||||||||
Traditional Life |
US | |||||||||||||||||||||||||||||||||||||||||||||||||
Universal Life |
US | |||||||||||||||||||||||||||||||||||||||||||||||||
Variable Annuities |
US | |||||||||||||||||||||||||||||||||||||||||||||||||
Annuities |
UK | |||||||||||||||||||||||||||||||||||||||||||||||||
Individual Protection |
UK | |||||||||||||||||||||||||||||||||||||||||||||||||
June 30, 2026 |
December 31, 2025 | |||||||
Investment contracts without DPF - Aegon risk |
||||||||
Investment contracts without DPF - Policyholder risk |
||||||||
Total investment contracts without DPF |
||||||||
| Aegon risk | Policyholder risk | |||||||||||||||
Movement schedule |
1H 2026 |
FY 2025 | 1H 2026 |
FY 2025 | ||||||||||||
Opening balance |
||||||||||||||||
Deposits |
||||||||||||||||
Withdrawals |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Interest credited |
||||||||||||||||
Fund charges released |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Net exchange differences |
( |
) | ( |
) | ||||||||||||
Transfer to / from other headings |
( |
) | ( |
) | ||||||||||||
Transfers to disposal groups |
( |
) | ( |
) | ||||||||||||
Other movements |
( |
) | ( |
) | ||||||||||||
Closing balance |
||||||||||||||||
| 36 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 14 | ||||
June 30, 2026 |
December 31, 2025 | |||||||
Capital funding |
||||||||
Operational funding |
||||||||
Total borrowings |
||||||||
June 30, 2026 |
Scenarios | 2027 | 2028 | 2029 | 2030 | Units | ||||||||||||||||
Interest rates |
Base | Interest Rates: 10-Year Treasury Constant Maturities, (% p.a., NSA1 ) | ||||||||||||||||||||
Interest rates |
Upside | Interest Rates: 10-Year Treasury Constant Maturities, (% p.a., NSA1 ) | ||||||||||||||||||||
Interest rates |
Downside | Interest Rates: 10-Year Treasury Constant Maturities, (% p.a., NSA1 ) | ||||||||||||||||||||
Unemployment rate |
Base | (%, SA) | ||||||||||||||||||||
Unemployment rate |
Upside | (%, SA) | ||||||||||||||||||||
Unemployment rate |
Downside | (%, SA) | ||||||||||||||||||||
House Price Index |
Base | Existing Single-Family Home Price: Median, (Ths. USD, SA) | ||||||||||||||||||||
House Price Index |
Upside | Existing Single-Family Home Price: Median, (Ths. USD, SA) | ||||||||||||||||||||
House Price Index |
Downside | Existing Single-Family Home Price: Median, (Ths. USD, SA) | ||||||||||||||||||||
Domestic GDP |
Base | Bil. Ch. 2012 USD, SAAR 2 | ||||||||||||||||||||
Domestic GDP |
Upside | Bil. Ch. 2012 USD, SAAR 2 | ||||||||||||||||||||
Domestic GDP |
Downside | Bil. Ch. 2012 USD, SAAR 2 | ||||||||||||||||||||
Equity |
Base | Standard & Poor’s (S&P); Moody’s Analytics Forecasted | ||||||||||||||||||||
Equity |
Upside | Standard & Poor’s (S&P); Moody’s Analytics Forecasted | ||||||||||||||||||||
Equity |
Downside | Standard & Poor’s (S&P); Moody’s Analytics Forecasted | ||||||||||||||||||||
December 31, 2025 |
Scenarios | 2026 | 2027 | 2028 | 2029 | Units | ||||||||||||||||
Interest rates |
Base | Interest Rates: 10-Year Treasury Constant Maturities, (% p.a., NSA1 ) | ||||||||||||||||||||
Interest rates |
Upside | Interest Rates: 10-Year Treasury Constant Maturities, (% p.a., NSA1 ) | ||||||||||||||||||||
Interest rates |
Downside | Interest Rates: 10-Year Treasury Constant Maturities, (% p.a., NSA1 ) | ||||||||||||||||||||
Unemployment rate |
Base | (%, SA) | ||||||||||||||||||||
Unemployment rate |
Upside | (%, SA) | ||||||||||||||||||||
Unemployment rate |
Downside | (%, SA) | ||||||||||||||||||||
House Price Index |
Base | Existing Single-Family Home Price: Median, (Ths. USD, SA) | ||||||||||||||||||||
House Price Index |
Upside | Existing Single-Family Home Price: Median, (Ths. USD, SA) | ||||||||||||||||||||
House Price Index |
Downside | Existing Single-Family Home Price: Median, (Ths. USD, SA) | ||||||||||||||||||||
Domestic GDP |
Base | Bil. Ch. 2012 USD, SAAR 2 | ||||||||||||||||||||
Domestic GDP |
Upside | Bil. Ch. 2012 USD, SAAR 2 | ||||||||||||||||||||
Domestic GDP |
Downside | Bil. Ch. 2012 USD, SAAR 2 | ||||||||||||||||||||
Equity |
Base | Standard & Poor’s (S&P); Moody’s Analytics Forecasted | ||||||||||||||||||||
Equity |
Upside | Standard & Poor’s (S&P); Moody’s Analytics Forecasted | ||||||||||||||||||||
Equity |
Downside | Standard & Poor’s (S&P); Moody’s Analytics Forecasted | ||||||||||||||||||||
1 |
NSA: Not seasonally adjusted. |
2 |
SAAR: Seasonally adjusted annual rate. |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 37 |
|
||||
Weightings |
Base | Upside | Downside | |||||||||
On June 30, 2026 |
||||||||||||
On December 31, 2025 |
||||||||||||
| Gross amount | ECL | |||||||||||||||||||||||||||||||
Debt securities |
Stage 1 | Stage 2 | Stage 3 | Total |
Stage 1 | Stage 2 | Stage 3 | |||||||||||||||||||||||||
1H 2026 |
(12-month ECL) |
|
(Lifetime ECL) |
|
(Lifetime ECL) ¹ |
|
gross amount |
(12-month ECL) |
|
(Lifetime ECL) |
|
(Lifetime ECL) ¹ |
|
Total ECL |
||||||||||||||||||
Opening balance |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Acquisition |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Disposal |
( |
) | ( |
) | ( |
) | ( |
) |
||||||||||||||||||||||||
ECL transfer from stage 1 to stage 2 |
( |
) | ( |
) | ||||||||||||||||||||||||||||
ECL transfer from stage 2 to stage 1 |
( |
) | ( |
) | ||||||||||||||||||||||||||||
ECL transfer from stage 2 to stage 3 |
( |
) | ( |
) | ||||||||||||||||||||||||||||
ECL transfer from stage 3 to stage 2 |
( |
) | ( |
) | ||||||||||||||||||||||||||||
ECL transfer from stage 3 to stage 1 |
( |
) | ( |
) | ||||||||||||||||||||||||||||
Impact on year-end ECL |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Amortizations through income statement |
||||||||||||||||||||||||||||||||
Unrealized gains/losses through equity |
( |
) | ( |
) | ( |
) |
||||||||||||||||||||||||||
Movements related to fair value hedges |
( |
) | ( |
) |
||||||||||||||||||||||||||||
Change in models |
( |
) | ||||||||||||||||||||||||||||||
Other movements |
( |
) | ( |
) |
||||||||||||||||||||||||||||
Transfer to/from other headings |
( |
) | ( |
) |
||||||||||||||||||||||||||||
Net exchange differences |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Closing balance |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
1 |
Including purchased credit impaired. |
| 38 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 16 | ||||
| Gross amount | ECL | |||||||||||||||||||||||||||||||
Debt securities |
Stage 1 | Stage 2 | Stage 3 | Total |
Stage 1 | Stage 2 | Stage 3 | |||||||||||||||||||||||||
FY 2025 |
(12-month ECL) |
|
(Lifetime ECL) |
|
(Lifetime ECL) ¹ |
|
gross amount |
(12-month ECL) |
|
(Lifetime ECL) |
|
(Lifetime ECL) ¹ |
|
Total ECL |
||||||||||||||||||
Opening balance |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Acquisition |
( |
) | - | ( |
) | ( |
) | |||||||||||||||||||||||||
Disposal |
( |
) | ( |
) | ( |
) | ( |
) |
||||||||||||||||||||||||
ECL transfer from stage 1 to stage 2 |
( |
) | - | - |
( |
) | - | - |
||||||||||||||||||||||||
ECL transfer from stage 1 to stage 3 |
( |
) | - | - |
- | - | - | - |
||||||||||||||||||||||||
ECL transfer from stage 2 to stage 1 |
( |
) | - |
( |
) | - | - |
|||||||||||||||||||||||||
ECL transfer from stage 2 to stage 3 |
- | ( |
) | - |
( |
) | - |
|||||||||||||||||||||||||
ECL transfer from stage 3 to stage 2 |
- | ( |
) | - |
- | ( |
) | - |
||||||||||||||||||||||||
ECL transfer from stage 3 to stage 1 |
- | ( |
) | - |
( |
) | - | - |
||||||||||||||||||||||||
Impact on year-end ECL |
- | - | - | - |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
Amortizations through income statement |
- | - | - | - |
||||||||||||||||||||||||||||
Unrealized gains/losses through equity |
( |
) | - | - | - | - |
||||||||||||||||||||||||||
Change in models |
- | - | - | - |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
Other movements |
( |
) | ( |
) |
- | - | - | - |
||||||||||||||||||||||||
Transfer to/from other headings |
( |
) | - | ( |
) | ( |
) |
- | - | - | - |
|||||||||||||||||||||
Net exchange differences |
( |
) | ( |
) | ( |
) | ( |
) |
||||||||||||||||||||||||
Closing balance |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
| 1 | Including purchased credit impaired. |
June 30, 2026 |
1 |
December 31, 2025 | ||||||
Group Eligible Own Funds |
|
|
||||||
Group SCR |
||||||||
Group Solvency ratio 2 |
||||||||
1 |
The solvency ratios are estimates and are not final until filed with the respective supervisory authority |
2 |
Including our share of a.s.r. Excess of Assets over Liabilities (minus own shares and minus minority interests) and SCR in our Group Solvency numbers. |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 39 |
|
||||
| 40 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 19 | ||||
Amounts in EUR millions (except per share data) |
1H 2026 |
1H 2025 | ||||||
Discontinued operations |
||||||||
Insurance revenue |
||||||||
Insurance service expenses |
( |
) | ( |
) | ||||
Insurance service result |
||||||||
Interest revenue on financial instruments calculated using the effective interest method |
||||||||
Interest income from instruments measured at FVPL |
||||||||
Other investment income |
||||||||
Results from financial transactions |
||||||||
Insurance finance income / (expenses) |
( |
) | ( |
) | ||||
Net reinsurance finance income / (expenses) on reinsurance held |
( |
) | ( |
) | ||||
Insurance net investment result |
( |
) |
( |
) | ||||
Interest revenue on financial instruments calculated using the effective interest method |
||||||||
Interest income from instruments measured at FVPL |
||||||||
Other investment income |
||||||||
Results from financial transactions |
||||||||
Investment contract income / (expenses) |
( |
) | ( |
) | ||||
Interest expenses |
||||||||
Other net investment result |
||||||||
Total net investment result |
( |
) |
||||||
Fees and commission income |
||||||||
Other operating expenses |
( |
) | ( |
) | ||||
Other income / (charges) |
||||||||
Other result |
( |
) |
( |
) | ||||
Result before tax from discontinued operations |
||||||||
Income tax (expense) / benefit |
( |
) | ( |
) | ||||
Result after tax from discontinued operations |
||||||||
Impairment loss on remeasurement of the disposal group |
||||||||
Net result from discontinued operations 1 |
||||||||
Earnings per share from discontinued operations |
||||||||
Basic earnings per common share |
||||||||
Basic earnings per common share B |
||||||||
Diluted earnings per common share |
||||||||
Diluted earnings per common share B |
||||||||
1 |
Net result from discontinued operations equals to the sum of Net result of Aegon UK (third party result) and the Inter-segment result ( intercompany result), both under 3.1 Segment results . |
1H 2026 |
1H 2025 | |||||||
Net result from discontinued operations |
||||||||
Items that will not be reclassified to profit or loss: |
||||||||
Remeasurements of defined benefit plans |
( |
) | ||||||
Items that may be reclassified subsequently to profit or loss: |
||||||||
Movement in foreign currency translation and net foreign investment hedging reserves |
( |
) | ||||||
Total other comprehensive income / (loss) from discontinued operations |
( |
) |
( |
) | ||||
Total comprehensive income / (loss) from discontinued operations |
||||||||
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 41 |
|
||||
June 30, 2026 |
||||
Assets |
||||
Cash and cash equivalents |
||||
Investments |
||||
Derivatives |
||||
Reinsurance contract assets |
||||
Deferred tax assets |
||||
Deferred expenses |
||||
Other assets and receivables |
||||
Intangible assets |
||||
Total assets held for sale |
||||
Liabilities |
||||
Reinsurance contract liabilities |
||||
Insurance contract liabilities |
||||
Investment contract liabilities with discretionary participation features |
||||
Investment contracts without discretionary participation features |
||||
Derivatives |
||||
Other liabilities |
||||
Total liabilities held for sale |
||||
1H 2026 |
1H 2025 | |||||||
Net cash inflow (outflow) from operating activities |
||||||||
Net cash inflow (outflow) from investing activities |
( |
) | ( |
) | ||||
Net cash inflow (outflow) from financing activities |
( |
) | ( |
) | ||||
Net cash inflow (outflow) from discontinued operations |
||||||||
Proceeds |
Number | Share price | GBP | EUR | ||||||||||||
Cash (in million) |
||||||||||||||||
Shares |
||||||||||||||||
Total consideration |
||||||||||||||||
Cost to sell |
( |
) | ||||||||||||||
Dividend |
( |
) | ||||||||||||||
Fair value less cost to sell |
||||||||||||||||
Carrying amount of Aegon UK |
||||||||||||||||
| 42 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
Notes to condensed consolidated interim financial statements Note 19 | ||||
| Fair value hierarchy | ||||||||||||||||
June 30, 2026 |
Level I | Level II | Level III | Total | ||||||||||||
Shares |
||||||||||||||||
Debt securities |
||||||||||||||||
Money market and other short-term investments |
||||||||||||||||
Other investments at fair value |
||||||||||||||||
Derivatives |
||||||||||||||||
Investments - Policyholder risk |
||||||||||||||||
Total financial assets measured at FVPL |
||||||||||||||||
Investment contracts without DPF - Policyholder risk |
||||||||||||||||
Derivatives |
||||||||||||||||
Total financial liabilities measured at fair value |
||||||||||||||||
| Transfers to disposal groups |
Total gains / (losses) in income statement 1 |
Purch- ases |
Sales | Settle- ments |
Net ex- change difference |
On June 30, 2026 |
Total URGL for the period 2 |
|||||||||||||||||||||||||
Derivatives |
( |
( |
||||||||||||||||||||||||||||||
Investments - Policyholder risk |
( |
|||||||||||||||||||||||||||||||
Total financial assets (FVPL) |
( |
|||||||||||||||||||||||||||||||
1 |
Includes impairments and movements related to fair value hedges. Gains and losses are recorded in the line item Results from financial transactions of the income statement. |
2 |
Total unrealized gains / (losses) for the period recorded in the P&L during which the financial instrument was in Level III. |
1H 2026 |
Insurance contracts (Non-PAA) |
Investment contracts with DPF | ||||||||||||||||||||||||||||||
Movement schedules by type of liability |
LFRC | LC | LFIC | Total | LFRC | LC | LFIC | Total | ||||||||||||||||||||||||
Net opening balance |
||||||||||||||||||||||||||||||||
Transfers to disposal groups |
||||||||||||||||||||||||||||||||
Insurance revenue |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Incurred claims and expenses |
||||||||||||||||||||||||||||||||
Onerous contract losses (and reversals) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Insurance service expenses |
( |
) |
( |
) |
||||||||||||||||||||||||||||
Investment components |
( |
) | ( |
) | ||||||||||||||||||||||||||||
Insurance service result |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||
Insurance finance (income) / expenses |
||||||||||||||||||||||||||||||||
Cash flows |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Net exchange differences |
||||||||||||||||||||||||||||||||
Net closing balance |
||||||||||||||||||||||||||||||||
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 43 |
|
||||
1H 2026 |
Insurance contracts (Non-PAA) | Investment contracts with DPF | ||||||||||||||||||||||||||||||
Movement schedules by measurement component |
BEL | RA | CSM | Total | BEL | RA | CSM | Total | ||||||||||||||||||||||||
Net opening balance |
||||||||||||||||||||||||||||||||
Transfers to disposal groups |
||||||||||||||||||||||||||||||||
Changes in estimates that adjust CSM |
( |
) | ( |
) | ||||||||||||||||||||||||||||
Changes in estimates that adjust onerous contracts |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Changes that relate to future service |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Earnings released from CSM |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Release of risk adjustment |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Revenue from policyholder tax expenses incurred |
( |
) | ( |
) | ||||||||||||||||||||||||||||
Changes that relate to current service |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Insurance service result |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
General model |
||||||||||||||||||||||||||||||||
Interest accreted to insurance contracts |
- | - | - | - | ||||||||||||||||||||||||||||
Variable fee approach |
||||||||||||||||||||||||||||||||
Change in fair value of the underlying assets |
||||||||||||||||||||||||||||||||
Change in fulfilment value - risk mitigation option |
( |
) | ( |
) | - | - | - | - | ||||||||||||||||||||||||
Insurance finance (income) / expenses |
||||||||||||||||||||||||||||||||
Premiums received |
||||||||||||||||||||||||||||||||
Claims, benefits and expenses paid |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Cash flows |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||
Net exchange differences |
||||||||||||||||||||||||||||||||
Net closing balance |
||||||||||||||||||||||||||||||||
1H 2026 |
||||||||
Movement schedule |
Aegon risk | Policyholder risk | ||||||
Opening balance |
||||||||
Transfers to disposal groups |
||||||||
Deposits |
||||||||
Withdrawals |
( |
) | ( |
) | ||||
Interest credited |
||||||||
Fund charges released |
( |
) | ||||||
Net exchange differences |
||||||||
Closing balance |
||||||||
| 44 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
| Disclaimer | ||||
Disclaimer
Cautionary note regarding non-IFRS measures
This document includes the following non-IFRS financial measures: operating result and valuation equity. Operating result is calculated by consolidating, on a proportionate basis, Aegon’s joint ventures and associated companies, except for its associate, ASR Nederland N.V. Operating result reflects Aegon’s profit before tax from underlying business operations and mainly excludes components that relate to accounting mismatches that are dependent on market volatility or relate to events that are considered outside of the normal course of business. Valuation equity represents the sum of shareholders’ equity and the Contractual Service Margin (CSM) after-tax (embedded value of unearned profits in insurance contracts). This measure is intended to provide a more comprehensive view of the Group’s economic value. Aegon believes that these non-IFRS measures, together with the IFRS information, provide meaningful supplemental information about the operating results of Aegon’s business, including insight into the financial measures that senior management uses in managing the business.
Local currencies
This document contains certain information about Aegon’s results, financial condition and revenue generating investments presented in USD for the Americas and in GBP for the United Kingdom, because those businesses operate and are managed primarily in those currencies. None of this information is a substitute for or superior to financial information about Aegon presented in EUR, which is the currency of Aegon’s primary financial statements.
Important information for investors and securityholders
This communication is not intended to and does not constitute an offer to sell, buy, or exchange or the solicitation of an offer to sell, buy, or exchange any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, purchase, or exchange of securities or solicitation of any vote or approval in any jurisdiction in contravention of applicable law. In connection with the proposed corporate reorganization that includes, among other things, the domestication and continuation of Aegon as a Delaware corporation (the “Redomiciliation”), Aegon will file a registration statement on a Form F-4, which includes a U.S. Shareholder Circular (the “Proxy Statement/Prospectus”), with the U.S. Securities and Exchange Commission (the “SEC”). Aegon plans to mail the definitive Proxy Statement/Prospectus to its shareholders in connection with the proposed Redomiciliation ahead of calling an extraordinary general meeting of shareholders contemplated in Q4 2026. INVESTORS AND SECURITYHOLDERS OF AEGON ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AEGON, ITS PROPOSED REDOMICILIATION AND RELATED MATTERS. Investors and securityholders will be able to obtain free copies of the definitive Proxy Statement/ Prospectus (when available) and other documents filed with the SEC by Aegon through the website maintained by the SEC at www.sec.gov. In addition, investors and securityholders will be able to obtain free copies of the documents filed with the SEC on Aegon’s website at www.aegon.com or by contacting Aegon’s Investor Relations, World Trade Center, Schiphol Boulevard 223,1118 BH Schiphol, The Netherlands, Tel: + 3120-259-2500, E-mail: ir@aegon.com.
Participants in the solicitation
Aegon, its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from Aegon’s securityholders in respect of the proposed transactions under the rules of the SEC. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Aegon’s securityholders. in connection with the proposed Redomiciliation, including a description of their respective direct or indirect interests, by security holdings or otherwise, is included in the Proxy Statement/Prospectus described above. Additional information regarding Aegon’s directors and executive officers regarding the interests of such potential participants is also included in Aegon’s 20-F, which was filed with the SEC on March 26, 2026. This document is available free of charge as described from the SEC’s website at www.sec.gov.
Forward-looking statements
The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, focus, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, could, is confident, will, and similar expressions as they relate to Aegon. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. In addition, any statements that refer to sustainability, environmental and social targets, commitments, goals, efforts and expectations and other events or circumstances that are partially dependent on future events are forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation, and expressly disclaims any duty, to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect the company’s expectations at the time of writing. Actual results may differ materially and adversely from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include, but are not limited to, the following:
| • | Changes in general economic and/or governmental conditions, particularly in Bermuda, the United States, the United Kingdom and, in relation to Aegon’s shareholding in ASR Nederland N.V., and Aegon’s asset management business, the Netherlands. |
| • | Civil unrest, (geo-) political tensions, military action or other instability in countries or geographic regions that affect our operations or that affect global markets. |
| • | Changes in the performance of financial markets, including emerging markets, such as: |
| ° | The frequency and severity of defaults by issuers in Aegon’s fixed income investment portfolios. |
| ° | The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds. |
| ° | The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds. |
| ° | The impact from volatility in credit, equity, and interest rates. |
| • | Changes in the performance of Aegon’s investment portfolio and a decline in the ratings of Aegon’s counterparties. |
| • | The effect of tariffs and potential trade wars on trading markets and on economic growth, both globally and in the markets where Aegon operates. |
| • | The lowering of one or more of Aegon’s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon’s ability to raise capital and on its liquidity and financial condition. |
| • | The lowering of one or more insurer financial strength ratings of Aegon’s insurance subsidiaries and the adverse impact such action may have on the written premium, policy retention, profitability and liquidity of its insurance subsidiaries. |
| • | The effect of applicable Bermuda solvency requirements, the European Union’s Solvency II requirements, and applicable equivalent solvency requirements and other regulations in other jurisdictions, in particular the United States, affecting the capital Aegon is required to maintain and our ability to pay dividends. |
| • | Changes in the European Commission’s or European regulator’s position on the equivalence of the supervisory regime for insurance and reinsurance undertakings in force in Bermuda. |
| • | Changes affecting interest rate levels and low or rapidly changing interest rate levels. |
| • | Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates. |
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 45 |
|
||||
| • | The effects of global inflation, or inflation in the markets where Aegon operates. |
| • | Changes in the availability of, and costs associated with, liquidity sources, such as bank and capital markets funding, as well as conditions in the credit markets in general, such as changes in borrower and counterparty creditworthiness. |
| • | Increasing levels of competition, particularly in the United States, the United Kingdom, emerging markets and, in relation to Aegon’s shareholding in ASR Nederland N.V. and Aegon’s asset management business, the Netherlands. |
| • | Catastrophic events, either manmade or by nature including, for example, acts of God, acts of terrorism, acts of war and pandemics could result in material losses and significantly interrupt Aegon’s business. |
| • | The frequency and severity of insured loss events. |
| • | Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon’s insurance products and management of derivatives. |
| • | Aegon’s projected results, which are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems that are subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect or should errors in those models escape the controls in place to detect them, future performance will vary from projected results. |
| • | Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations. |
| • | Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations. |
| • | Customer responsiveness to both new products and distribution channels. |
| • | Third-party information used by Aegon, which may prove to be inaccurate and/or change over time (as methodologies and data availability and quality continue to evolve) and therefore impact our results and disclosures. |
| • | Operational risks (such as system disruptions or failures, security or data privacy breaches, cyberattacks, human error, failure to safeguard personally identifiable information, changes in operational practices or inadequate controls including with respect to third parties with which Aegon does business) which may disrupt Aegon’s business, damage its reputation and adversely affect its results of operations, financial condition and cash flows. |
| • | Aegon’s failure to swiftly, effectively, and securely adapt and integrate emerging technologies. |
| • | The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon’s ability to complete, or obtain regulatory approval for, acquisitions and divestitures, integrate acquisitions, and realize anticipated results from such transactions, and its ability to separate businesses as part of divestitures. In particular, in relation to the Proposed Redomiciliation, (i) the proposed Redomiciliation may not be completed in a timely manner or at all; (ii) the failure to realize the anticipated benefits of the proposed Redomiciliation; (iii) the possibility that any or all of the various conditions to the consummation of the proposed Redomiciliation may not be satisfied or waived; (iv) the effect of the pendency of the proposed Redomiciliation on our ability to retain and hire key |
| personnel, or its operating results and business generally and (v) the effects of the proposed Redomiciliation on trading, liquidity and the price of Aegon’s securities. |
| • | Aegon’s failure to achieve anticipated levels of earnings or operational efficiencies, as well as other management initiatives related to cost savings, Cash Capital at Holding, gross financial leverage and free cash flow. |
| • | Changes in the policies of central banks and/or governments. |
| • | Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business. |
| • | Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of, or demand for, Aegon’s products. |
| • | The consequences of an actual or potential break-up of the European Monetary Union in whole or in part and the potential consequences of European Union countries leaving the European Union. |
| • | Changes in laws and regulations, or the interpretation thereof by regulators and courts, including as a result of comprehensive reform or shifts away from multilateral approaches to regulation of global or national operations, particularly regarding those laws and regulations related to ESG matters, those affecting, for example, the ability of Aegon’s operations to hire and retain key personnel, the taxation of Aegon companies, the products Aegon sells, the attractiveness of certain products to its consumers and Aegon’s intellectual property. |
| • | Regulatory changes relating to the pensions, investment, insurance industries and enforcing adjustments in the jurisdictions in which Aegon operates. |
| • | Standard setting initiatives of supranational standard setting bodies, such as the Financial Stability Board and the International Association of Insurance Supervisors, or changes to such standards that may have an impact on regional (such as EU), national (such as Bermuda) or US federal or state level financial regulation or the application thereof to Aegon. |
| • | Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon’s reported results, shareholders’ equity or regulatory capital adequacy levels. |
| • | Rapid changes in the landscape for ESG responsibilities, which lead to potential challenges by private parties and governmental authorities, and/or changes in ESG standards and requirements, including assumptions, methodology and materiality, or a change by Aegon in applying such standards and requirements, voluntarily or otherwise, that may affect Aegon’s ability to meet evolving |
| 46 | | Interim financial information for the six-month period ended June 30, 2026 - Unaudited |
| Disclaimer | ||||
| standards and requirements, or Aegon’s ability to meet its sustainability and ESG-related goals, or related public expectations, which may also negatively affect Aegon’s reputation or the reputation of its board of directors or its management. |
| • | Unexpected delays, difficulties, and expenses in executing against Aegon’s environmental, climate, or other ESG targets, goals and commitments, and changes in laws or regulations affecting us, such as changes in data privacy, environmental, health and safety laws. |
| • | Reliance on third-party information in certain of Aegon’s disclosures, which may change over time as methodologies and data availability and quality continue to evolve. These factors, as well as any inaccuracies in third-party information used by Aegon, including in estimates or assumptions, may cause results to differ materially and adversely from statements, estimates, and beliefs made by Aegon or third parties. Moreover, Aegon’s disclosures based on any standards may change due to revisions in framework requirements, availability of information, changes in its business or applicable governmental policies, or other factors, some of which may be beyond Aegon’s control. Additionally, Aegon’s discussion of various ESG and other sustainability issues in this document or in other locations, including on our corporate website, may be informed by the interests of various stakeholders, as well as various ESG standards, frameworks, and regulations (including for the measurement and assessment of underlying data). As |
| such, our disclosures on such issues, including climate-related disclosures, may include information that is not necessarily “material” under US securities laws for SEC reporting purposes, even if we use words such as “material” or “materiality” in relation to those statements. ESG expectations continue to evolve, often quickly, including for matters outside of our control; our disclosures are inherently dependent on the methodology (including any related assumptions or estimates) and data used, and there can be no guarantee that such disclosures will necessarily reflect or be consistent with the preferred practices or interpretations of particular stakeholders, either currently or in future. |
This document contains information that qualifies, or may qualify, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (596/2014). Further details of potential risks and uncertainties affecting Aegon are included in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
| Interim financial information for the six-month period ended June 30, 2026 - Unaudited | 47 |
aegon.com